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ABSTRACT 
 
Off-label prescribing is a common and legal practice in the United States.  However, off-
label prescribing occurs oftentimes with inadequate evidence of effectiveness.  Such practice, 
especially when prescribing for disease conditions different from approved clinical indications 
(indication-based off-label prescribing), brings about controversy and raises different issues with 
various stakeholders.  Although indication-based off-label prescribing offers advantages in terms 
of providing innovative therapy, it raises concerns because the safety and efficacy of such use 
may not be evaluated adequately.  Thus, the objective of the study was to examine whether 
pharmacists are willing to influence physicians while evaluating an indication-based off-label 
medication order.  Based on the extended social power typology originally proposed by French 
and Raven (1965), the study examined the role of relative expert power, perceived 
appropriateness, and perceived negative relational consequences on pharmacist’s willingness to 
influence using rationality tactic. 
Pharmacists practicing in hospitals were recruited from the membership rolls of state 
affiliates of the American Society of Health-System Pharmacists (ASHP).  The state affiliates 
were requested to distribute to their members an invitation to participate that contained a link to 
the survey instrument.  The study employed a 2 X 2 experimental design in which relative expert 
power and appropriateness were manipulated using a hypothetical vignette.  Respondents who 
reported practicing in a hospital were randomly assigned to one of the four experimental groups. 
Responses from 267 pharmacists were available for analysis.  After consistency 
inspection, 242 pharmacist respondents were included in the analysis to examine the various 
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propositions.  Results of the analysis showed that, in general, pharmacists were willing to 
influence physicians to ensure rationality of indication-based off-label prescribing.  Although 
small in magnitude, pharmacists did express concern about negative impact on inter-professional 
relationship quality that might arise due to influence attempts.  Indeed, the effect of perceived 
expert power differential between the physician and pharmacist and the effect of perceived 
appropriateness of the off-label medication order on willingness to influence were strongly 
(p<0.05) moderated by perceived impact on relationship quality.  In addition, the perceived 
expert power differential was associated with pharmacists’ willingness to influence.  
Pharmacists’ willingness to influence increased as perceived appropriateness decreased.   
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CHAPTER 1 
INTRODUCTION 
Physicians prescribe medications with an expectation that they are safe and effective.  
Despite these two basic assumptions, it is understood that a medication may fail to provide the 
expected therapeutic effect or have associated with its use, side effects.  In other words, an 
approved medication, prescribed for a labeled (approved) indication, may have associated with it 
any outcome from harmful to safe and from ineffective to effective.  In addition to prescribing 
practices that are consistent with product labeling, prescribers are granted the right to prescribe 
medications outside of approved indications or allowed to choose therapies that have not yet 
received approval from the Food and Drug Administration (FDA).  Off-label prescribing is an 
example of such a privilege.  Off-label prescribing can be considered an experimental treatment, 
a standard therapy, or state-of-the-art pharmacotherapeutic practice.  Naturally, off-label 
prescribing has drawn a lot of attention in the media and among policy makers and has been 
subject of academic inquiry for years. 
Off-label Prescribing 
Off-label prescribing is the act of prescribing of a medication in a way that is not 
authorized or approved by a drug approval authority in a country (e.g., the FDA in the United 
States) (Cuzzolin, Zaccaron, and Fanos, 2003).  There are different types of off-label use of 
medications.  An off-label prescription may include an unapproved indication, dosage, 
formulation, route of administration, population, contraindication or a combination thereof 
(McIntyre et al., 2000; Conroy, 2002; Neubert et al., 2004).  Off-label prescribing is a widely 
prevalent pharmacotherapeutic practice across many countries including the United States 
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(Chalumeau et al., 2000; Conroy et al., 2000; Pandolfini et al., 2002; Radley, Finkelstein, and 
Stafford, 2006).  Additionally, off-label prescribing has been found to be practiced in ambulatory 
care and institutional care and in different practices settings including office-based practice 
(Ekins-Daukes et al., 2004; Radley, Finkelstein, and Stafford, 2006), and hospital practice 
(Turner et al., 1999; Bajcetic et al., 2005).  
The extent of off-label prescribing had been shown to vary across different patient 
populations.  It has been estimated that the extent of off-label prescribing may be up to 40% in 
adults (Brosgart et al., 1996) and 90% in pediatric patients (Conroy, McIntyre, and Choonara, 
1999; Conroy et al., 2000).  However, the prevalence rates of different types of off-label use 
(e.g., indication-based, dosage-based etc.) in adult and pediatric patient groups differ greatly.  In 
children, as may be expected, the most frequent category of off-label use is dosage-based.  
Studies have found dosages used in this population were both higher and lower than what was 
indicated (Conroy, McIntyre, and Choonara, 1999; Pandolfini et al., 2002).  Off-label prescribing 
for indications other than recommended ones (indication-based off-label prescribing) has been 
found to be prevalent in the pharmacotherapy of both adult (Chen et al., 2009) and pediatric 
patients (Pandolfini et al., 2002). 
The practice of off-label prescribing varies across drug class.  Substantial variations are 
observed in off-label use of different functional classes of medicines.  For example, psychiatric 
medicines, anticonvulsants, cardiac medicines, antiasthmatics, allergy medicines, and medicines 
for peptic ulcers and dyspepsia are more likely to be prescribed off-label compared to other 
medications, such as analgesics (Radley, Finkelstein, and Stafford, 2006).  Off-label prescribing 
was less common relatively and infrequent in medications used for glycemic control (<1%), 
analgesia (6%), and in antihyperlidemics (7%).  Off-label prescribing was highly prevalent 
3 
 
among cardiac medications (e.g., antianginals, anticoagulants, and antiarrythmics) (46%), 
anticonvulsants (46%), asthma therapies (42%), and psychiatric medicines (31%) (Radley, 
Finkelstein, and Stafford, 2006).  In fact, one study found that more than 70% of patients 
receiving anticonvulsant therapies were prescribed such medications off-label on the basis of 
patient age or indication (Chen et al., 2005).  Drug class differences in off-label use of medicines 
may also vary depending on patient population.  A study conducted in the UK observed that 
systemic antibacterial agents were the largest category of medicines prescribed off-label, 
followed by asthma therapies among all medicines prescribed off-label (based on unapproved 
dose) in children in general practice (McIntyre et al., 2000). 
Off-label prescribing occurs across different medical specialties (Li et al., 1998; McIntyre 
et al., 2000; Haw and Stubb, 2005).  Specialists may be more aware of current therapeutic 
developments or have better access to clinical guidelines or information on experimental uses of 
medicines through peers (Lin, Phan, and Lin, 2006).  For example, the in one study it was 
observed that the cardiac specialists were more likely to prescribe β-blockers off-label as 
compared to the general physicians. 
The extent of off-label prescribing of medicines has been shown also to vary by the intent 
of the therapy and disease stage (US General Accounting Office (GAO), 1991; Brosgart et al., 
1996).  For example, 68% cancer patients who were receiving palliative therapy were prescribed 
at least one medication off-label compared to only 41% of the patients receiving curative care.  
The proportion of the patients who received at least one medication off-label was higher in 
metastatic cancer than localized cancer (GAO, 1991).  However, there is no agreement in the 
literature on whether the extent of off-label prescribing increases when there exists a lack of 
consensus regarding the best pharmacotherapeutic option (GAO, 1991; Brosgart et al., 1996).  
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Off-label prescribing of medications has many different origins.  For some disease states, 
medications enter the market for very specific indications with narrow therapeutic goals.  Once 
in the market, these medications are tried for different off-label indications and in some cases, 
off-label indications become approved indications.  For example, paclitaxel, initially approved 
for second-line treatment of ovarian cancer, was later approved for the treatment of breast cancer 
and non-small-cell lung cancer (Boos, 2003).  Aspirin was not approved until 1998 to reduce 
heart attacks even though it has been prescribed by physicians for many years (O’Reilly and 
Dalal, 2003).  One of the most prominent examples is sildenafil, for which initial approval for 
marketing was for pulmonary arterial hypertension (PAH) (Klein and Tabarrok, 2004).  In fact, 
some off-label use is so common that it finds a place in some official compendia.  For example, 
sodium valproate is listed in the British National Formulary for the treatment of mania in bipolar 
affective disorder (Haw and Stubbs, 2005).  Interestingly, off-label uses of some medicines 
exceed their labeled uses.  For example, off-label prescriptions of rituximab showed near-
exponential growth indicating statistically significant increase in propensity of prescribing for 
off-label indications compared to approved indications over time (Kocs and Frendrick, 2003). 
Rationale for Off-label Prescribing 
Many reasons have been cited by prescribers for using medications off-label (e.g., advice 
by consultants, lack of alternatives) (Ekins-Daukes et al., 2005).  In general, knowledge about 
off-label use broadens a physician’s ability to relieve symptoms or cure diseases that are 
refractory to standard pharmacotherapy or for which there does not exist an effective standard 
therapy (Li et al., 1998).  However, evidence suggests that off-label prescribing decisions may 
not be always justified or, at least, are questionable.  One study found that in the office-based 
practice setting, medications that are prescribed off-label with lack of support include 
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gabapentin, amitriptyline, and risperidone, and with support are isosorbide mononitrate, 
albuterol, digoxin, and atenolol (Radley, Finkelstein, and Stafford, 2006).  Additionally, it was 
observed that among all off-label uses, more cases (15%) lacked scientific evidence than those 
(6%) with strong scientific evidence.  This finding is supported by a review published in 2007 by 
the Agency for Healthcare Research and Quality (AHRQ) that highlighted the lack of evidence-
based off-label prescribing of psychiatric medications. 
Implications of Off-label Prescribing 
Off-label prescribing is neither illegal nor unwarranted nor always inappropriate 
(Tabarrok, 2000).  However, its practice may present uncertainty about safety and effectiveness 
(Nightingale, 2003).  Off-label prescribing, especially in circumstances where it would be 
considered inappropriate, has the potential to cause harm to different stakeholders including 
patients and prescribers (Turner et al., 1999; Neubert et al., 2004). 
Off-label prescribing has implications for increased cost for medication use.  One study 
found that in a single academic institution $1.1 million was spent between 1997 and 2001 on 
rituximab prescribed off-label compared to $335,000 for FDA approved indications.  However, 
this figure did not include various costs incurred by patients or pharmacy preparation, 
administration etc. 
Professional organizations (e.g., American Academy of Pediatrics, Committee on Drugs, 
2002) have issued guidelines for prescribers, who may prescribe medications off-label.  
Generally, it is advocated that the decision to prescribe off-label should be based on expert 
medical judgment and sound scientific evidence.  Gazarian et al. (2006) recommended a decision 
algorithm for evaluating the appropriateness of any proposed off-label prescribing including 
differentiation between practice and research and judgment of evidence.  The existence of off-
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label prescribing guidelines may prove useful for ensuring appropriate use and thus, the adoption 
of any such recommendations has the potential of improving off-label prescribing decisions.  
However, one key to the successful application of such recommendations is the critical appraisal 
of and the evaluation of applicability of evidence.  Health care professionals should monitor and 
evaluate off-label prescribing so that risk-effectiveness potential can be detected early.  This begs 
the question how can health care achieve that goal? 
Opportunity for Pharmacists 
It has been documented that pharmacists’ involvement in the medication selection 
decision results in improvement in prescribing patterns and patient care (Lipton et al., 1992; 
Hanlon et al., 1996; Finley et al., 2002).  Pharmacists have provided and continue to provide a 
broad spectrum of services including consultations to physicians, medication monitoring, and the 
dissemination of objective information to prescribers (Pedersen, Schneider, and Scheckelhoff, 
2008).  Given that pharmacists have fulfilled a variety of patient care roles, how can we utilize 
pharmacists’ expertise and service orientation to improve indication-based off-label use of 
medicines?  Do they have or perceive any role to play in that context?  Two leading professional 
pharmacy organizations – the American Pharmacists Association (APhA) and the American 
Society of Health-System Pharmacists (ASHP) – support off-label prescribing.  “The freedom 
and responsibility to make drug therapy decisions that are consistent with patient-care needs is a 
fundamental precept supported by ASHP” and is not believed to be limited by FDA-approved 
product labeling (ASHP, 1992).  ASHP also supports the role of the pharmacist to provide 
medication information and clinical practice standards regarding off-label use of medications.  
APhA has adopted a similar positions and policies and states that collaboration should be formed 
between pharmacists and other healthcare providers to evaluate information related off-label 
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prescribing of medications.  However, past studies that have examined off-label prescribing from 
the perspective of pharmacy or pharmacists (Ansani et al., 2006; Stewart et al., 2007) did not 
address pharmacist-level service specific to off-label prescribing. 
Given that philosophy of pharmaceutical care has envisioned pharmacists as patient 
advocates as well as medication experts, the objective of this study was to explore pharmacists’ 
perceptions of their role in off-label prescribing.  Specifically, using a theory of social power 
(French and Raven, 1959), the study investigated whether pharmacists were willing to influence 
different types of physicians who wrote an indication-based off-label prescription on the basis of 
its level of appropriateness as perceived by pharmacists.  As such, the following propositions 
were investigated. 
P1: The pharmacist’s perceived relative expert power in relation to the physician is 
positively associated with the pharmacist’s willingness to influence off-label 
prescribing. 
P2: The perceived appropriateness of prescription medication is negatively associated 
with the pharmacist’s willingness to influence off-label prescribing. 
P3: The effect of the pharmacist’s relative expert power on the pharmacist’s willingness 
to influence off-label prescribing is moderated by the perceived appropriateness of 
prescription medication. 
P4 The effect of the pharmacist’s perceived relative expert power on willingness to 
influence off-label prescribing is moderated by the perceived impact on relationship 
quality with the physician as perceived by the pharmacist. 
 
SIGNIFICANCE OF THE STUDY 
Understanding off-label prescribing from pharmacists’ perspective is important for 
several reasons.  Off-label prescribing, if not judiciously done, has the potential of causing 
detrimental effects.  In situations where off-label prescribing results in harm, pharmacists along 
with the prescriber may be liable for injury under conditions of negligence (Campbell, 1995).  In 
addition, from an ethical perspective, the pharmacist is just as much an advocate for patient well-
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being as is the physician.  As such, the principles of nonmaleficence and beneficence should 
oblige pharmacists to question the use of medications to ensure that patients experience the 
maximum therapeutic benefit at the least possible risk of harm (Abella, 2003).  Thus, off-label 
prescribing has implications for pharmacists.  Although recommendations and normative 
guidelines by professional organizations such as APhA or ASHP regarding the role of 
pharmacists in off-label prescribing have been issued, it is important to examine whether such 
normative recommendations are consistent with pharmacists’ perceptions of their role and 
responsibilities. 
Off-label prescribing, especially indication-based off-label prescribing, oftentimes is 
driven by the physician’s perception of unmet pharmacotherapeutic needs.  Once disseminated 
appropriately, such uses may serve as a knowledge repository.  In fact, indication-based off-label 
use has been posited as a potential avenue for creating new knowledge (Demonaco, Ali, and 
Hippel, 2006) in a cost-effective manner, if appropriately managed.  Our understanding of the 
off-label prescribing process from the perspective of pharmacists – specifically the role of 
perceived power in appropriate and desirable situations – may provide us with crucial 
information to help design and implement the process of reengineering knowledge. 
The issue of off-label prescribing has concerned various stakeholders including 
lawmakers, economists, lay public, payers, and the media.  Off-label prescribing presents issues 
of risk assessment and management as safety and efficacy of such use is not oftentimes well 
assessed.  In addition, from a societal point of view, off-label use of medications – specifically, 
indication-based off-label prescribing – may not be a cost-effective treatment option, at least in 
some cases.  Thus, such practice has the potential to waste valuable and scant resources.  
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CHAPTER 2 
LITERATURE REVIEW 
PRESCRIBING 
Medication prescribing is one of the principal forms of treating illness (Raisch, 1996).  
Prescribing behavior can be viewed as a reasoned action that is preceded by the medication 
choice decision that consists of two steps.  First, an evoked set – a small set of possible 
treatment options, including non-drug therapies for a diagnosis – is generated.  Once the 
evoked set is formed, a prescriber chooses a specific therapy for a patient out of the 
“available” options (Denig et al., 1990 as cited in Denig and Haaijer-Ruskamp, 1992).  This 
may be based on either active problem solving that involves the process of weighing utilities, 
values, desirability, and expectancies of outcomes of each alternative (Segal and Hepler, 
1985; Denig and Haaijer-Ruskamp, 1992) or habitual behavior, generally seen for frequently 
occurring or non-life threatening disease states (Denig and Haaijer-Ruskamp, 1992).  
However, medical-related outcomes such as efficacy, adverse effects, cost, patient health 
status, and comorbidities as well as non-medical factors are considered when prescriptions 
are written (Hemminki, 1975; Denig and Haaijer-Ruskamp, 1992; Scott, Shiell, and King, 
1996).  Nonmedical factors that influence prescribing can be broadly categorized as 
demographic and practice-related variables and psychosocial variables. 
Demographic and Practice Variables Associated with Prescribing 
Physician’s age, gender, country of training, and relationship with colleagues, 
practice characteristics (e.g., number of patient seen or practice day etc.), practice setting 
(e.g., HMO or hospitals) are some of the factors believed to influence prescribing 
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(Hemminki, 1975; Davidson et al., 1994; Raisch, 1996; Sleath and Shih, 2003).  Differences 
between general physicians and other specialties have been observed prescribing patterns of 
particular groups of medications (Chin et al., 1997; Sleath and Shih, 2003) or in the treatment 
of particular diseases (Freund et al., 1989; Saarela and Engestrom, 2003). 
In addition, patients’ characteristics such as age (McKinlay, Potter, and Feldman, 
1996; Sleath and Shih, 2003), gender (Scott, Shiell, and King, 1996), ethnicity (Daumit et al., 
2003) and socioeconomic status (Scott, Shiell, and King, 1996), insurance status (Sleath and 
Shih, 2003; DeWitt et al., 2006).  Such associations have been found even after controlling 
for medical and nonmedical factors (Hohmann, 1989; Scott, Shiell, and King, 1996).  
Interactions between physician and patient characteristics have also been noted and may 
influence prescribing by physicians (Weisse et al., 2001; Hamberg, Risberg, and Johansson, 
2004). 
Psychosocial Factors Related to Prescribing 
A host of psychosocial factors have been found to influence prescribing decisions.  
Patient perceived knowledge, locus of control, assertiveness, assessment of the physician's 
expert power, physician's relinquishment of control, and professional assessment of patient 
requests have been proposed as antecedents that influence prescription decisions (Verbrugge 
and Steiner, 1985; Krupat et al., 1999; White and Johnson, 2002).  Despite objective medical 
training, physicians remain human actors and become socially-conditioned to show 
stereotyping either consciously or unconsciously (McKinlay, Potter, and Feldman, 1996).  It 
is within the framework of socio-cultural and economic influences, and biomedical 
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knowledge and probabilities of outcomes, that prescribing decisions are made (Eisenberg, 
1975). 
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OFF-LABEL PRESCRIBING 
Reasons for Prescribing Off-label 
Different rationale for off-label prescribing has been cited in the literature.  Despite 
efforts to standardize treatment through the development and use of clinical guidelines by 
professional organizations (e.g., the American College of Cardiology), lack of awareness 
about appropriate use may be one of the explanations for off-label prescribing.  Physicians 
may not be aware that each medication in a therapeutic class may not be approved by the 
FDA for the same indication(s) (Lin, Phan, and Lin, 2006).  For example, among ACE 
inhibitors only lisinopril has been approved for acute myocardial infarction (Radley, 
Finkelstein, and Stafford, 2006).  Apart from lack of awareness, some off-label prescribing 
may happen because of lack of concern for such use.  Prescribing of certain medications in 
some indications, such as for pain management, are so well-established that clinicians may 
be unaware that the medication is being used for off-label indications (Douglas-Hall, Fuller, 
and Gill-Banbam, 2001).  This may explain, in part why, generally, older medications are 
prescribed more often for off-label indications as compared to newer medications.  However, 
on the contrary, Barbui et al. (2004) observed that the proportion of off-label use of second 
generation antipsychotic agents were higher than that of the first generation agents.  
Therefore, certain characteristics of medications (e.g., range of indications) may be 
underlying factors for off-label use of those agents.  
Physicians may prescribe a medication off-label because of an incorrect belief that the 
medication is approved by the FDA for that use.  For instance, Li et al. (1998) observed a 
positive correlation between the off-label use and belief in FDA approval for a medication 
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and noted that many dermatologists misidentified off-label drug/disease pairs as approved by 
the FDA.  However, some off-label prescribing may arise from logical extensions of FDA-
approved indications.  For example, certain off-label uses of antibiotics can be justified on 
the basis of laboratory experiments on disease-causing microorganisms (Radley, Finkelstein, 
and Stafford, 2006) although uncertainty about interactions among drugs, patients, and 
comorbidities still remain. 
Disease characteristics may also be associated with off-label prescribing.  Off-label 
medication use may occur if an existing treatment does not cure or there is a lack of 
agreement in treatment.  Laetz and Silverman (1991) noted that off-label prescribing is 
prevalent in chemotherapy regimens for types of cancers that are more difficult to treat and is 
used often in circumstances in which there are no cures, no agreement on standardized 
treatment, or when treatments mainly are palliative.  Similarly, a study by the US General 
Accounting Office (GAO) (1991) noted that off-label usage increases generally in treating 
cases that are more difficult to treat.  For example, off-label prescribing occurs in the 
treatment of cancer that has advanced to a point that is no longer curable, when 
chemotherapy is ineffective relatively, when patients are receiving second and third lines of 
treatment, or when physicians are desperately searching for a cure or a better way to palliate 
the disease (GAO, 1991).  In addition, for some diseases such as non-small cell lung cancer 
and cystic fibrosis, off-label uses of existing therapies are the only choice or therapy of 
choice (Poole and Dooley, 2004).  Physicians treating such diseases or physicians who have 
needs that are not served currently by extant options may look for innovative ways to treat 
their patients by applying their understanding of the disease process and/or the mechanism of 
action of the medication.  In fact, the physicians who claimed to have discovered off-label 
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uses independent of pharmaceutical companies expressed a high need for that particular use 
of the medication in their patient care (Demonaco, Ali, and Hippel, 2006). 
The efficacy and safety of medications are known through controlled clinical trials or 
other forms of clinical studies and medications are approved on the basis of those results.  
However, in some situations it may be difficult to recruit special patient groups (e.g., 
children) to serve as study subjects.  In such cases, clinicians do not feel deterred to prescribe 
medications off-label.  In fact, in situations where there is less evidence available for 
uncommon diseases, off-label prescribing may be more frequent (Haw and Stubbs, 2005a).  
Similar problems may arise due to patients’ lack of awareness and a general unwillingness to 
participate in clinical trials; combined this makes it difficult to conduct and thus generalize 
the results of such trials (Institute of Medicine, 2000).  In other cases, executing the clinical 
trials necessary to receive new indications is not commercially viable (e.g., populations too 
small or disease too rare) (Tabarrok, 2000).  Therefore, some medication label use fails to 
receive the necessary FDA approval and the practice of off-label prescribing persists. 
Another issue that is an important consideration in off-label medication use is 
polypharmacy.  Oftentimes, patients have multiple conditions.  As such, one medication used 
to treat one condition may be contraindicated for use in patients with other comorbidities or 
when used with other medications intended to treat comorbidities.  However, a lack of 
therapeutic options may make it difficult for physicians to avoid prescribing a medication 
that is apparently contraindicated as described above.  In one study that examined prescribing 
behaviors using secondary data, it was found that the physicians prescribed β-blockers off-
label for health conditions for which the use of β-blockers is cautioned (Lin, Phan, and Lin, 
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2006).  However, it is not known if physicians systematically assess benefits/risks before 
prescribing a medication off-label. 
The role of satisfaction has been studied as a contributing factor for off-label 
prescribing.  In a Delphi panel study, it was observed that satisfaction with available 
therapies for off-label indication is less than that for approved indications (Kos, Wertheimer, 
and Mrhar, 2005).  Therefore, low levels of satisfaction or dissatisfaction with existing 
therapies may be a reason that provides impetus to prescribe a medication off-label (Mack, 
2003; Kos, Wertheimer, and Mrhar, 2005). 
Factors that Negatively Affect Off-label Prescribing 
The risk of adverse events and perceived threat of litigation associated with off-label 
prescribing may prevent physicians from prescribing medicines off-label (Kocs and 
Fendrick, 2003).  The practice of defensive medicine presents an interesting paradox.  The 
practice of defensive medicine generally may inhibit off-label prescribing.  However, such 
practice may promote off-label prescribing if physicians fear legal actions for failing to 
prescribe off-label in presence of published evidence (Atkins, 1998).  Reimbursement by 
third party payers may negatively affect off-label prescribing.  Some managed care 
organizations may deny coverage of off-label indications because they consider the use 
investigational or experimental (Demonaco, Ali, and Hippel, 2006).  Moreover, physicians 
might have to seek prior authorization for reimbursement of off-label medications.  Fear of 
such administrative hassles might deter physicians from off-label prescribing (Laetz and 
Silberman, 1991).  In recent years, the patient’s share of the cost of prescription medications 
has been increasing.  As a result. off-label prescribing may be negatively affected if patients 
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are not willing to share the additional cost over and above that expected for medication use 
according to labeling. 
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Level of Evidence, Comparative Effectiveness, and Potential Adverse Effects 
The existing evidence base surrounding off-label prescribing has received much 
attention from researchers.  Whether or not enough evidence exists for off-label prescribing 
to be justifiable has also been debated.  Chen et al. (2005) examined the off-label use of 
anticonvulsant medications to differentiate types of off-label use on the basis of degree of 
evidence in a Medicaid population.  It was found that between 19% - 57% of off-label 
prescribing of anticonvulsant medications was not substantiated by controlled studies.  A 
similar finding was made in a more recent study where it was noted that among all off-label 
uses of medicines, a substantial majority (73%) had little or no scientific evidence for clinical 
efficacy (Radley, Finkelstein, and Stafford, 2006).  Many atypical antipsychotic medicines 
are being prescribed off-label for the treatment of dementia, depression, and other psychiatric 
disorders.  Although off-label prescribing with limited or no support outnumbered that of 
supported off-label use, it is most strikingly prevalent in psychiatry (96% of off-label use 
occurred with limited or no support) (Radley, Finkelstein, and Stafford, 2006).  In 2007, 
AHRQ published a report reviewing evidence on efficacy and comparative effectiveness of 
atypical antipsychotics prescribed off-label for the treatment of different psychiatric 
disorders.  The study found either no or moderate to very low evidence supporting the off-
label use of atypical antipsychotics.  Specifically, there was moderate evidence for use of 
riserperidone and quetiapine, low for olanzepine and no studies for ziprasidone or 
aripiprazole for the treatment of obsessive-compulsive disorder.  In addition, as reported by 
the AHRQ review, the results from some studies conflicted that of others.  For example, 
olanzepine, and quetiapine showed conflicting evidence in studies that compared atypical 
antipsychotics with placebo for the treatment of bipolar disorder (AHRQ, 2007).  
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Additionally, an earlier review of off-label use in psychiatric medication use concluded that 
although some evidence exists supporting the use of atypical antipsychotics in off-label 
situations, generalization of these observations to all clinical cases might not be valid 
(Fountoulakis et al., 2004).  This statement may be further strengthened by the fact that many 
published studies investigating the efficacy of off-label use of medications included only 
small number of patients (Schelenker, et al., 2006).  Moreover, when prescribers were asked 
to provide the rationale for their off-label prescribing and the evidence they used while 
prescribing off-label, for the majority of off-label prescriptions, physicians were able to quote 
randomized controlled trials (RCTs), Cochrane Reviews, or consensus statements by expert 
panels; however, in a large number of instances (41%), the level of evidence cited by the 
physicians was more vague (Haw and Stubbs, 2005a). 
Researchers have examined also the relationship between the off-label use of 
medicines and adverse drug events.  In fact, the greatest concern posed by the use of off-label 
medications is the probable unanticipated adverse drug reaction (ADR) (Conroy, 2002).  A 
number of studies have examined the relationship between off-label prescribing and risks of 
complication or adverse reactions in pediatric populations (Turner et al., 1999; Horen, 
Monstastruc, and Lapeyre-Mestre, 2002; Neubert et al., 2004).  In fact, many studies have 
identified increased risks of adverse drug reactions associated with off-label medication use.  
Horen, Monstastruc, and Lapeyre-Mestre (2002) found an increased risk of ADR was 
associated with the use of off-label medications prescribed for unapproved indications, 
particularly in infants.  In a prospective surveillance of prescriptions in pediatric wards, 
Turner et al. (1999) found a higher but nonsignificant risk of ADR associated with 
unlicensed and off-label medications when compared with licensed uses and 74% of 
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medications causing severe ADRs were prescribed in an unlicensed or off-label manner.  
Moreover, the risk of ADR was found to be associated with the percentage of off-label use or 
exposure to at least one off-label medication use event (Turner et al., 1999, Horen, 
Monstastruc, and Lapeyre-Mestre, 2002).  A study of pediatric outpatients observed that of 
all adverse events, 42.4% were associated with the use of off-label medications and more 
than 20% were associated with dose-related or indication-based off-label uses (Ulfer, 
Kimland, and Bergman, 2004).  Although adverse events caused by off-label and that by on-
label were not compared specifically, Neubert et al. (2004) observed a higher incidence of 
ADR in the patient group prescribed off-label or unlicensed medications than in the group 
treated with licensed medications.  However, whether the effect was due to off-label 
prescribing or the complexities of illness was not clear.  Off-label uses of atypical 
antipsychotics were associated with weight gain, sedation, extrapyramidal symptoms, and 
neurological symptoms such as fatigue, headache, dizziness etc. (AHRQ, 2007).  It is 
interesting to note that though elevated risk of death in elderly dementia patients treated off-
label with atypical antipsychotics was small, comparable benefits were also small and further 
research is required to confirm the efficacy and safety of atypical antipsychotics prescribed 
for off-label indications (AHRQ, 2007).  Use of off-label dosages of atypical antipsychotics 
deserves further scrutiny.  While physicians’ concern for the use of these potent medicines in 
elderly population is laudable, the use of low-doses may cause adverse effects and may fail to 
elicit therapeutic response (Kogut, Yam, and Dufresne, 2005).  Therefore, while there may be 
some evidence of benefits, caution is required when medicines are used for off-label 
indications.  Finally, ‘fen-phen’ is a classic example that illustrates the need for vigilance 
regarding the potential adverse events that may be caused by off-label prescribing.  
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Fenfluramine and phentermine were approved individually for short-term appetite 
suppression.  However, ‘fen-phen’, the combination of the two medications prescribed off-
label, caused heart-valve disease in women (Tabarrok, 2000).  Unfortunately, off-label use is 
oftentimes without protocol, monitoring, or adequate long-term follow-up for ADRs.  
Moreover, these ADRs may not be identified until large number of patients are affected 
(Zindrick, 2000). 
Is Off-label Prescribing Good or Bad? 
Off-label prescribing is legal and in general, embraced by physicians and other 
stakeholders including payers, health care institutions, pharmaceutical companies, and the 
FDA (Nightingale, 2003).  However, efforts have been made to regulate the promotion of 
off-label use by pharmaceutical companies.  Arguments have been made both favoring and 
opposing the promotion of off-label use by pharmaceutical companies.  However, 
historically, the FDA has avoided any conflict with physicians’ decisions to prescribe 
medications for off-label indications or off-label in any other manner (O’Reilly and Dalal, 
2003).  In fact, physicians are given the freedom to lawfully prescribe medications off-label 
as it is believed to provide incentives to aid patients (Cohen, 1997; Blum, 2002) and as such, 
off-label prescribing may be a socially desirable behavior in some instances.  Despite 
permissive laws and regulations, it is expected that caution will be exercised while 
prescribing medications off-label.  Though not required by law, it is considered generally 
good practice to inform patients about the nature of treatment and to seek informed consent.  
If a patient is injured, he or she can file malpractice claims and tort claims against the 
physician for off-label prescribing or even the failure to prescribe off-label use, if 
appropriate.  Potential liability increases as the physician decides to or not to deviate from 
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customary medical standard of care.  Therefore, continuous communication between 
physicians, patients, and others in the medical community may reduce the risks of liability 
(O’Reilly and Dalal, 2003).  In many instances, physicians’ subjective knowledge, clinical 
experience, case reports and open-label trials are the basis of off-label prescribing.  While 
these are valuable for directing future research, they may not constitute a sufficient basis for 
treatment decisions (Hamer et al., 2002; Chen et al., 2005).  In fact, it may be such that there 
exists – due to lack of well-designed studies or laws or guidelines mandating clinical trial 
evidence – systematic underlying biases limiting generalizability (Chen et al., 2005).  
Regardless of the quality of evidence, off-label prescribing, especially of new medications, 
should be based on comparative studies showing advantages in effectiveness and/or safety 
and/or cost-effectiveness over existing alternatives, if any (Gazarian et al., 2006).  Therefore, 
off-label prescribing warrants more stringent oversight.  There is some evidence that 
interdisciplinary efforts do occur; one study with specialized and small number of cases 
observed that the psychiatrists consulted with pharmacists, multidisciplinary team members 
and patients’ relatives while prescribing off-label medications (Haw and Stubbs, 2005a, 
2005b).  However, it is not known if this constitutes regular practice.  Regardless of legality 
of off-label prescribing, it has been suggested that physicians should carefully weigh the 
benefit/risk ratio before, during, and after off-label prescribing (Torres, 1994).  Even though 
physicians have knowledge about patients, their medical history, and current clinical status, 
they have a difficult but important job in deciding whether a specific off-label use may be 
safer and more effective than all existing alternatives (Nightingale, 2003).  Rigorous 
judgment, continuous evaluation, and close monitoring by healthcare professionals regarding 
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off-label medication use may reduce the risks of harm, detect lack of effectiveness, ensure 
early benefit, and maximize patient benefit (Dresser, 2006). 
PHARMACISTS AND OFF-LABEL PRESCRIBING 
Information in the published literature about pharmacist involvement in and attitudes 
toward off-label prescribing is scant.  Stewart et al. (2007) is one of the first known studies 
investigating off-label prescribing from the perspective of pharmacy.  Through a survey of 
community pharmacists in the UK, the authors found that majority of community 
pharmacists became familiar with the concept of off-label prescribing through their 
dispensing experience.  Age and dose were primary reasons that pharmacists believed that 
off-label prescribing happened.  Interestingly, 78% of pharmacists surveyed believed that 
they have a professional duty (responsibility) to inform the physician prescribing medications 
off-label.  Despite this stated concern, only 39% of the pharmacists in the sample stated they 
would always contact the physician if high dose of β-agonist or steroids were prescribed off-
label whereas 74% would always contact the physician if high dose paracetamol were 
prescribed off-label.  Ansani et al. (2006) studied off-label medication use in US academic 
medical centers (AMC) to determine how many AMCs have policies regarding off-label or 
‘innovative’ off-label use and beliefs about off-label or ‘innovative’ off-label medication use 
as a source of problems within the AMC.  Only a small number of AMC were reported to 
have a policy regarding off-label use and an even smaller number of AMCs had policies 
regarding innovative off-label use.  Surprisingly, “problems never addressed by physicians 
and pharmacists” was cited as a significant reason for the AMC not having policy.  Lack of 
data to support intervention, high cost, and potentially high risk/benefit ratio of the 
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intervention were also cited as issues.  Fewer than half of the AMCs require follow up action 
and aggressive monitoring of off-label or ‘innovative’ off-label medication use. 
PRESCRIBING PROBLEMS AND PHARMACIST INTERVENTIONS 
In the complex process of medication prescribing and use, pharmacists are believed to 
play a pivotal role.  Their role at the interface between medication distribution and 
medication use process is very important for the prevention of medical errors resulting from 
inappropriate prescribing.  Because pharmacists represent the final point at which prescribing 
problems can be identified and corrected, they can ensure that quality care is delivered to 
patients (Rupp, DeYoung, and Schondelmeyer, 1992).  Moreover, due to training in 
therapeutics, in the last two decades, the clinical role of pharmacists has gained prominence 
and has been expanded.  In fact, the pharmacists’ clinical role is acknowledged by many 
professional organizations of physicians and it has been suggested that pharmacists’ expertise 
in medication therapy can be utilized through collaborative medication therapy management 
with physicians (Keely, 2002).  As their clinical role in managing medication therapy 
continues to grow, so does their importance and ability to influence prescribing (Carroll, 
2003).  Moreover, it has been suggested that pharmacists may serve as educators, with 
ultimate goal of optimizing patient outcomes through influencing physicians’ prescribing 
behavior (Grindrod, Patel, and Martin, 2006). 
Pharmacist Recommendations and Acceptance by Physicians 
Pharmacists are involved in the effort and measures to optimize prescribing.  Past 
studies have found that pharmacists are willing to be involved in interventions related to 
medication therapy and able to identify and correct prescribing problems and to influence 
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prescribing in different ways (Carroll, 2003).  Prescribing problems in which interventions 
were made by pharmacists include inappropriate dosage and schedule, pharmacokinetic 
monitoring, inappropriate combination, therapeutic duplication, inappropriate choice, 
potential drug reaction and interaction, medication-use evaluation, and non-formulary 
order/policy (Tamai et al., 1987; Lipton et al., 1992; Strong and Tsang, 1993; Pedersen, 
Schneider, and Scheckelhoff, 2008).  Physicians, in variety of settings, have generally shown 
positive attitude toward pharmacist recommendations.  Sulick and Pathak (1996) compared 
physicians’ and pharmacists’ perceptions on the importance of various clinical activities 
including patient specific recommendations of therapeutic alternatives, recommendations 
based on pharmacokinetic monitoring, and patient specific suggestions to change prescribed 
regimen to prevent drug interactions or adverse events.  It was found that the physicians rated 
the importance of general clinical activities significantly and consistently higher than did the 
pharmacists.  Such a positive attitude may be reflected in the fact that the physicians 
oftentimes accept and implement pharmacists’ recommendations (Leape et al., 1999; Lee et 
al., 2002; Carroll, 2003).  A recent national survey of US hospitals observed that the adoption 
rate of pharmacists’ recommendations is highly encouraging (Pedersen, Schneider, and 
Scheckelhoff, 2008). 
Outcomes of Pharmacist Recommendations 
It should be noted that medication use evaluation by pharmacists is likely to detect 
medication errors which otherwise might go undetected; decreased medication error rates are 
associated with pharmacist-provided medication information service, ADR management, 
medication protocol management, and pharmacist participation on medical rounds (Leape et 
al., 1999; Bond, Raehl, and Franke, 2002).  Pharmacists’ involvement with antibiotic 
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prescribing has been found to result in positive outcomes with respect to medication choice, 
dosage used, and appropriate utilization (Dickerson, Mainous, and Carek, 2000).  Lipton et 
al. (1992) found that the clinical pharmacists significantly improved the overall 
appropriateness of physician prescribing, specifically, problems related with less than 
optimal prescribing, no-indication prescribing, and dosage-related issues.  Similarly, Lee et 
al. (2002) observed that in over 30% of cases, pharmacist recommendations either improved 
or resolved the problems; between 81 - 92% of cases potential harm would have been the 
result if the pharmacist had not intervened.  Numerous studies have been demonstrated that 
pharmacist recommendations prevent medication errors and minimize adverse events 
(Hanlon et al., 1996; Leape et al., 1999).  Overall, pharmacist services resulted in alternative 
therapy that was safer but equally effective and was associated with direct cost savings and 
cost avoidance (Lee et al., 2002; Schumock et al., 2003).  
COLLABORATION AND COMMUNICATION BETWEEN THE PHARMACIST 
AND THE PHYSICIAN 
Given the complexity of pharmacotherapeutic treatment plans, some degree of 
collaboration between the physician and the pharmacist in healthcare settings is necessary in 
order to provide comprehensive, efficient, and effective treatment to patients.  Collaboration 
is a complex and sophisticated process that includes coordination of individual actions, 
cooperation in planning and decision-making, and sharing of goals, responsibilities, and 
power based on knowledge and expertise among other things (Henneman, Lee, and Cohen, 
1995).  Many investigators have found that physician-pharmacist collaboration has resulted 
in improved quality of prescribing (Spinewine et al., 2007) and improved patient care 
outcomes (Boudreau et al., 2002; Borenstein et al., 2003).  However, Henneman, Lee, and 
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Cohen (1995) pointed out that effective communication is crucial and antecedent to effective 
collaboration between the pharmacist and the physician to ensure desired patient care as 
envisioned by the pharmaceutical care paradigm.  However, it has also been recognized that 
the practice of pharmaceutical care has the potential of causing undesirable tension or 
inevitable conflict between the physician and the practicing pharmacist (Hepler and Strand, 
1990).  Therefore, there is a need for successful communication between physicians and 
pharmacists in order for pharmacists to be able to provide the entire spectrum of activities 
associated with the provision of pharmaceutical care.  Although research on communication 
between different actors in healthcare abounds (see Ellingson, 2002 for a review), only a few 
studies (e.g., Ranelli and Biss, 2000) examined pharmacist-physician communication.  
Unfortunately, although pharmacist-physician communication occurs daily, over 95% of this 
activity was related to refills and less than 1% of pharmacist communication was directly 
with the physician (Kallail and Stanton, 2006).  Drawing on Brown and Levinson’s (1987) 
conceptualization of face or social impression, Lambert (1995; 1996) investigated 
determinants of pharmacy students’ and pharmacists’ decisions to communicate strategically 
with physicians to protect their face.  Brown and Levinson (1987) proposed three factors that 
determine the weightiness of face threatening acts (FTAs) and that influence the selection of 
politeness (face-saving communication) strategies.  These factors are power of the person to 
whom communication is targeted, social distance between the speaker and the listener, and 
culture-specific ranking of the issue at hand.  In other words ranking refers to the extent of 
the imposition or the degree of severity of the FTA.  The authors claimed that the sum of the 
three factors provides an index of the weightiness of the FTA.  As the weightiness of the 
FTA increases, the speaker is likely to adopt more polite communication strategies.  Lambert 
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(1995) observed, as posited by the framework of Brown and Levinson (1987), that the culture 
specific ranking of the FTA influenced the types of politeness strategy used by the pharmacy 
students.  Alternative medication recommendations were considered more threatening than 
allergy reports and the students were concerned about taking care of the negative face wants 
of the physicians (communication recipients).  Lambert (1996), in a later study, found that 
pharmacists made medication recommendations more politely than when they presented 
allergy reports.  Interestingly, some pharmacists in the study refrained from any making 
recommendation in order to manage physicians’ negative face wants.  However, contrary to 
the work of Brown and Levinson, the author did not find support for the influence of power 
and social distance on the communication strategy chosen although it was observed that 
hospital pharmacists were more assertive in making recommendations than were community 
pharmacists.  However, Lambert (1996) recognized inadequate conceptualization of power 
and the need for further study on the effect of power on communication.  In a similar note, 
Ellingson (2002) argued that communication among healthcare team members is likely to be, 
at least partially, affected by its members’ relative power. 
BASES OF SOCIAL POWER AND INFLUENCE 
Social power has been conceived as the resources that impart a person ability to 
influence another person to do what the former wants the latter to do (Raven, Schwarzwald, 
and Koslowsky, 1998).  Influence is closely related to the concept of power.  In fact, the 
terms power and influence are sometimes used interchangeably.  However, power differs 
from influence in that the former refers to the potential and the latter to the actual use of the 
power.  French and Raven (1959) defined influence as a force that an influencing agent (O) 
can use to induce compliance by changing the beliefs, attitudes, or behaviors of a target (P) 
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of influence.  French and Raven (1959) originally conceptualized five bases of social power 
(namely, Reward, Coercion, Legitimacy, Expertise and Reference) which have been 
elaborated on and further differentiated from research and theories in cognitive social 
psychology, attitude and attitude change, and organizational psychology (Raven, Schwarzald, 
and Koslowsky, 1998).  More recently, Raven (1992; 1993) revised and expanded the bases 
of power and proposed the power-interaction model of interpersonal influence. 
Reward power is defined as P’s perception of O’s power or ability to administer 
positive valances and to remove or decrease negative valances.  Strength of reward power 
increases as the magnitude of reward and P’s perception of probability that O mediates the 
reward increase.  More recently, Raven (1992; 1993) classified reward power – the ability to 
provide tangible rewards – as impersonal reward power and personal reward power, which is 
based on P’s perception that O’s personal approval or liking of the target can be rewarding. 
Coercive power, like reward power, is of two types: personal and impersonal (Raven, 
1992;1993).  Impersonal coercion is defined as P’s perception that O has the ability to deliver 
tangible punishments for noncompliance and personal coercion refers to situation when O 
threatens to disapprove or dislike P for failing to conform.  The strength of coercive power is 
a function of the magnitude of negative valance of threatened punishments multiplied by P’s 
perceived probability of avoiding punishment by complying (French and Raven, 1959). 
In its original conceptualization (French and Raven, 1959), legitimate power refers to 
the power that stems from P’s internalized values dictating that O has right to influence and P 
has an obligation to comply.  It was conceived to consist of three bases namely, cultural (age, 
intelligence, caste and physical characteristics), social structure (hierarchy), and designation.  
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Legitimacy has been further elaborated into four distinct types (Raven, 1992; 1993).  
Legitimate position is defined as P’s perception that O has the right to influence based on 
organizational position or professional role.  Legitimate reciprocity refers to P’s perception 
that P has obligation to comply with O who has done something to benefit P.  Legitimate 
equity stems from P’s perception that P is obligated to comply in order to compensate for 
inconvenience or harm caused by P to O or an effort put in by O.  Legitimacy of dependence 
is defined as P’s perception that P has obligation to help O who is in need of assistance. 
Referent power is based on P’s identification or feeling of oneness of P with O or 
desire for such an identity.  The greater the attraction of P to O, the is greater the 
identification of P with O and consequently, the greater is the referent power of O.  Referent 
power can be positive as described above or negative in which case P prefers to disidentify 
with the person seemingly unappealing or unattractive (Raven, 1992; 1993). 
Expert power stems from P’s perception that O possesses knowledge or expertise in 
areas relevant and interesting to P.  The strength of expert power depends on the extent of 
O’s knowledge as perceived by P in relation to P’s and against an absolute standard.  Expert 
power results in primary social influence on P’s cognitive structure.  For expert power to 
influence, it is required that P believes that O knows and trusts that O tells the truth.  Such 
conceptualization was later referred as positive expert power.  There is negative expert power 
when P distrusts O and does opposite of what O does or desires P to do (Raven, 1992; 1993). 
Later, informational power was added to the bases of power described above.  
Informational power is defined as the ability of O to present information or logical argument 
to P in order to influence.  Specifically, self-evident facts fit P’s cognitive structure and 
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impersonal acceptance of the truth of such facts is independent of relationship between P and 
O.  Information can be presented in direct form and indirect form.  Indirect information is 
found to be especially useful when a person in low power position attempts to influence a 
person in high power position (Raven, 1992; 1993). 
Research on social power has yielded different typologies (Yukl and Falbe, 1991; 
Peiro and Melia, 2003) in addition to that originally proposed by French and Raven.  One 
dichotomy that has been consistently recognized is “soft” versus “hard” power bases.  A 
commonsensical interpretation is that soft (weak) bases tend to be more subtle, positive, and 
noncoercive while hard (harsh) bases tend to be more overt, punitive, and “heavy-handed” 
(Erchul, Raven, and Ray, 2001).  In other words, the soft base describes power that relies on 
the influencing agent’s personal assets whereas the harsh or hard base refers to power that is 
granted to the individual by the nature of his or her status (Schwarzwald, Koslowsky, and 
Ochana-Levin, 2004).  Within Raven’s (1992; 1993) framework of power-interaction model, 
the soft base includes positive expert, positive referent, direct informational, legitimate 
dependence, and personal reward power.  The hard bases indicates legitimate reciprocity, 
impersonal coercive, legitimate equity, impersonal reward, personal coercive, and legitimate 
position power (Raven, Schwarzwald, and Koslowsky, 1998).  Although little difference 
exists in the pattern, other studies that utilized the IPI (Erchul, Raven, and Ray, 2001; Erchul, 
Raven, and Whichard, 2001, Koslowsky, Schwarzwald, and Ashuri, 2001) provided support 
that power bases can be broadly subsumed under the soft/hard two-factor solution. 
STUDIES ON POWER AND INFLUENCE 
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Over the years, French and Raven’s power typology has become a central concept in 
the study of organizational psychology and social interactions.  In the organization setting, it 
has been applied to study superior-subordinate, subordinate-superior, and peer perceptions 
and the use of power (Yukl and Falbe, 1991; Koslowsky, Schwarzwald, and Ashuri, 2001) 
and outcomes and effectiveness of various power bases (see Podsakoff and Schriesheim, 
1985 for a review).  Koslowsky and Schwarzwald (1993) observed higher status individuals 
such as supervisors have greater variety of power and control of resources as compared to 
low status individuals.  Similarly, Yukl and Falbe (1991) reported that middle level managers 
had more downward power because of greater coercive power than did lower level managers 
and peers recognized legitimacy, expertise, and persuasiveness were the most important 
reasons for carrying out tasks.  It has been contended and empirically supported that an agent 
chooses particular influence strategies based on his or her evaluation of the parameters of 
agent-target relationship, including the relative status of each person (Raven, 1993; Stahelski 
and Paynton, 1995).  In line with that argument, perceptions of relative power were measured 
by other researchers (Yukl and Falbe, 1991; Somech and Drach-Zahavy, 2002).  It was 
observed that relative power affected superiors’ choice of strategies (Somech and Drach-
Zahavy, 2002) and higher status person or superiors chose strategies that follow from power 
bases whereas low status persons or subordinates chose influence tactics involving less 
control of resources (Stahelski and Paynton, 1995).  
In the health care setting, perception of power, use of power, and outcomes of such 
uses have been examined.  To influence hospital personnel, infection control nurses in US 
hospitals who were high in self-efficacy were more likely to report using informational and 
expert power and nurses with low self-efficacy legitimate and coercive power (Raven, 
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Freeman, and Haley, 1982 as cited in Raven, 1992).  Manfredi (1996) examined the role of 
power in the leadership activities by nurse managers.  Nurse managers reported the use of 
legitimate power in situations that required upholding standards, enforcing policies, and 
hiring, firing, or disciplining staff, expert power to bring about change, and referent power 
when they sought cooperation and agreement.  While exercising referent power, the nurse 
managers asked for support from staff and communicated that they are valued and important.  
Past research reported that information, expertise, position and dependence legitimacy, and 
referent power were the top-rated power bases recognized by both hospital and nursing staff 
and their supervisors and there was a high congruence in compliance perception between the 
two groups (Raven, Schwarzwald, and Koslowsky, 1998; Koslowsky, Schwarzwald, and 
Ashuri, 2001).  Physicians had used expert power to influence nurses (Raven, Freeman, and 
Haley, 1982 as cited in Raven, 1992).  It has been suggested that informational power and 
referent power, if used by physicians, may be very effective in gaining patient compliance 
(Erchul and Raven, 1997). 
Pharmacists’ power and influence has also been studied in the organizational context.  
Pharmacists’ power may have multitude of sources.  For example, pharmacists may have 
requisite expertise and be in the best position to analyze and evaluate the medications for 
formulary decisions (Balu, O’Connor, and Vogenberg, 2004) or pharmacists may be a 
member of subcommittees acting as a facilitator between the P&T committee and the 
subcommittee (Nair, Coombs, and Ascione, 2004).  Pharmacists on the P&T committee 
exerted substantial power over formulary decision-making although pharmacists’ sources of 
influence were not investigated (Mannebach et al., 1999; Bagozzi, Ascione, and Mannebach, 
2005).  Using French and Raven’s typology, Arntson (2002) observed that the bases of power 
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that were considered the most important determinants of the pharmacist’s influence on 
formulary admission decisions included expert, information, and referent power.  However, 
the importance of sources of power was found to vary by the number of members on the 
P&T committee.  Pharmacists’ expert and information power were found to be most 
influential in large committees while expert and referent power in smaller committees 
(Arnston, 2002).  Thus, the growing importance of P&T and pharmacists’ role in the P&T 
and other related subcommittees may give pharmacists a sense of power.  Such sources of 
influence may be grouped under what Raven (1992; 1993) described as third party influence. 
Social power bases have been applied in context of school teacher consultation.  
There have been arguments about which social power bases are most relevant to teacher 
consultation.  Reviewing published studies that applied French and Raven’s original 
conceptualization of power, Erchul and Raven (1997) concluded that there is some evidence 
that expert power and referent power are linked to school teacher consultation.  Erchul, 
Raven, and Ray (2001) made further investigation of school psychologists’ perceptions of 
power based on the new conceptualizations.  The authors concluded that consultants viewed 
informational power and expert power, together labeled as credibility, to be most effective 
and more likely to be used.  Researchers has also examined if both the consultant and the 
consultee held similar views of the effectiveness of the consultant’s use of power (Erchul, 
Raven, and Whichard, 2001).  Even though both the consultant and the consultee viewed 
direct informational and positive expert power to be more effective, the authors cautiously 
concluded that both parties share similar views about the effectiveness of social power in 
consultation when more global indicators are considered, but hold divergent views when 
more specific indicators are considered.  Although the use of certain power bases may be 
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perceived effective by both the consultants and the consultee, it becomes effective in reality 
only if those powers are applied when attempting to influence.  Recently, Wilson (2008) 
studied likelihood of the use of power bases unlike previous studies that focused on 
perceived effectiveness of power bases (Raven, Schwarzwald, and Koslowsky, 1998; Erchul, 
Raven, and Whichard, 2001).  As such, consultants were more likely to use soft than harsh 
power bases.  Specifically, direct information power, positive expert power and referent 
power are significantly more likely to be used.  Getty (2006) concluded that likelihood of 
using soft bases, in general, is positively related – specifically, each of the three power 
described above was positively and significantly related – to consultants’ self-perceptions of 
effectiveness.  Finally, Lippitt et al. (1952) concluded individuals with high attributed power 
tend to initiate more social influence attempt than low power individuals. 
LIMITATIONS OF STUDIES ON OFF-LABEL PRESCRIBING AND 
PHARMACISTS’ ROLE 
Off-label prescribing, if not judiciously done, has the potential of causing detrimental 
effects.  In situations where off-label prescribing results in harm, pharmacists along with the 
prescriber may be liable for injury under conditions of negligence.  One way to mitigate such 
liability is by assuring the appropriateness of such use.  Consultation with the prescriber in 
order to determine the rationale, documentation, as well as review of current scientific and 
professional literature, and applying critical professional judgment may minimize such 
liability (Campbell, 1995).  In addition, from an ethical perspective, the pharmacist is just as 
much an advocate for the patient’s well-being as is the physician.  Principles of 
nonmaleficence and beneficence oblige pharmacists to question the use of medications, 
certainly those used off-label, to ensure the medication offers maximum therapeutic benefit 
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to patients at the least possible risk of harm (Abella, 2003).  Therefore, off-label prescribing 
has strong implications for pharmacists.  Yet, past research regarding off-label prescribing 
inadequately examined issue from the perspective of pharmacists.  It has been found that 
pharmacists have been consulted in some instances regarding off-label prescribing (Haw and 
Stubbs, 2005a).  However, other studies examined opinions and beliefs about off-label 
prescribing only (Ansani et al., 2006; Stewart et al., 2007).  Moreover, the results of these 
studies are not generalizable in other hospital practice settings because of the sampling 
design and because research subjects who practiced in community pharmacies or teaching 
hospitals. 
Physicians consider indication and effectiveness of a medicine as the two most 
important of the ten parameters of appropriate medication prescribing (Samsa et al., 1994).  
However, while studying community pharmacists Stewart et al. (2007) focused on pediatric 
off-label prescribing where off-label prescribing occurs largely due to unapproved 
population, dosage, and formulation.  Indication-based off-label prescribing deserves special 
attention because of inherent risk; however, existing research has failed to provide much 
needed information about this issue. 
It has been reported that indication-based prescribing is prevalent in AMCs.  
However, only half of the AMCs require Pharmacy and Therapeutic Committee (P&T) 
review of policy on off-label or innovative off-label use (Ansani et al., 2006).  It is largely 
unknown about off-label prescribing and the policies that govern that activity in community 
hospitals because this has not yet been examined in that context.   
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Leape et al. (1999) observed that pharmacists took responsibility to ensure safety 
identifying unsafe conditions and need for process improvement.  Whether pharmacists go or 
are willing to go through the same deliberation in case of indication-based off-label 
prescribing has not been studied.  Pharmacists have been often envisioned as professional 
best positioned to make sound decision and judgments concerning medication therapy.  
Flood and Scott (1978) argued that for optimal functioning, professional groups must be in a 
position to exercise power largely, compared to other groups, over decisions concerning their 
sphere of competence.  Campagna (1995) argued that although pharmacists performing at 
prescriptive and consultative levels may significantly influence prescribing, few pharmacists 
are performing at corrective level of decision-making and even fewer in prescriptive and 
consultative level.  Under the light of such findings, how pharmacists who are providing 
clinical services influence off-label prescribing merits attention.  Campbell (1995) suggested 
that if the pharmacist is not convinced of the appropriateness of the off-label use of 
medications, a decision not to comply with the physician’s decision would be proper course 
of action.  However, whether pharmacists providing clinical pharmacy services are willing to 
influence prescribers in the context of inappropriate off-label prescribing is not yet known. 
Ellingson (2002) argued that communication among health care team members is 
affected by power, hierarchy, and privilege within the specific hospital or other health care 
institutions.  However, social power and its impact on pharmacist-physician communication 
have not been investigated well.  Although power has been conceptualized as 
multidimensional construct (French and Raven, 1959), past research (Lambert, 1996) 
conceptualized and examined power as one-dimensional construct.  While it is evident that 
pharmacists possess some power (Arnston, 2002), Lambert (1996) examined only 
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pharmacists’ perception of physician’s expert power - neither relative perception of power 
nor the other bases of power.  Relative perceptions of power in the context of off-label 
medication product selection and use may affect willingness to/ likelihood of communication 
or influence.  In addition, it is not known whether perception of power and its effect on 
pharmacists’ decisions to influence has changed since Lambert examined pharmacist-
physician communication more than a decade ago; given the way the scope of pharmacy 
practice has evolved in the last few years, there is the potential for these relationships to be 
different.  
In sum, in the context of indication-based off-label prescribing, there exists a need for 
investigation on attitude and perceived roles and responsibilities of pharmacists providing 
clinical pharmacy services in community hospitals.  Specifically, it is worth examining the 
effect of perceived social power on pharmacists’ intent of influence concerning indication-
based off-label prescribing. 
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CHAPTER 3 
CONCEPTUALIZATION, RESEARCH METHOD, AND TECHNIQUES 
CONCEPTUALIZATION 
The following describes the psychological process of assessing power and its 
potential and the preparation for influence attempts.  The power/interaction model of 
interpersonal influence (Raven, 1992) provided the foundation for the conceptual framework 
(Figure 1) for this study of pharmacist power and willingness to influence.  The model can be 
used to study power-influence dynamics from both the agent’s perspective as well as the 
target’s perspective.  The model provides a process view of power and influence attempts 
and describes various antecedents to and consequences of power and influence attempts. 
Adapted from Raven (1992) 
Control Variables 
• Assessment of social power 
• Information  
• Referent 
• Legitimate power of dependence 
• Attitude 
• Perceived responsibility 
• Perceived relative expert power 
• Perceived appropriateness 
Willingness to 
influence 
- Perceived impact on 
relationship quality 
Figure 1:  PROPOSED CONCEPTUAL FRAMEWORK 
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The influencing agent, within the context of this study, the hospital pharmacist, 
assumed a motivated and rational person, assesses the power bases that may be available to 
use as well as how effective those power bases will be in implementing changes.  The 
argument for the assessment of power appears to be intuitive as the influencing agent may 
have multiple influence strategies available for use and the choice of a particular influence 
tactic would be based on his or her evaluation of power over the target (Fung, 1991).  The 
influencing agent’s assessment of power inherently is relative in nature.  Researchers have 
found empirical evidence of the effect of relative power on influence behavior (Somech and 
Drach-Zahavy, 2002).  Because both physicians and pharmacists train in 
pharmacotherapeutics and share the domain of knowledge relevant for medication use, 
perception of relative power – at least for some power bases (e.g., expert power) that are 
relevant to the shared domain – is an appropriate representation rather than absolute 
perception.  As such, this approach was thought to capture appropriately the hospital 
pharmacist’s assessment of power. 
Once the assessment of power is completed, the influencing agent will evaluate the 
potential of influence.  The influencing agent may carry out a cost-benefit analysis of the 
influence strategy.  It can be argued that such analyses are influenced critically by various 
factors such as personal norms and values, secondary gains and losses, and time, costs, and 
effort required for achieving the desired outcomes (Raven, 1992).  Here, the influencing 
agent may consider the potential relational, situational, and/or ethical ramifications of using a 
particular power base (Getty, 2006).  For example, the influencing agent might ask if the use 
of a seemingly effective power base affects relationship or if it is ethically and professionally 
appropriate in a given context. 
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After having assessed the available power bases and costs and benefits of their use, 
one would expect that at this point the agent might prepare for the influence attempt (Raven, 
1992). This preparation for influence attempts can manifest itself in several ways.  For 
example, the influencer can enhance (e.g., displaying diplomas or degrees) or emphasize 
(e.g., showing expertise or advanced knowledge for expressing expert power) activities that 
support his or her power position.  However, before the agent decides to enhance or prepare 
the stage for an influence attempt, it can be argued, the agent must decide that s/he is going to 
influence.  Such a decision may be accentuated by favorable appraisals of power bases and 
potential outcomes.  In other words, the agent’s willingness to influence precedes the 
preparation for an influence attempt.  This argument appears valid for three reasons.  First, 
because of the differential nature and sources of various power bases, different types of 
power may need different stage-setting requirements, attributes, and tools.  Willingness to 
use different bases of power may dictate specific preparations for influence attempts.  For 
example, for legitimate power of reciprocity, an influencing agent might try to evoke 
ingratiation and describe how one favored the target on previous occasions.  Second, factors 
such as personal preferences or attributes may affect the use of power.  For example, 
infection control nurses who perceived themselves competent were more likely to use expert 
and information power (Raven, Freeman, and Haley, 1982 as cited in Raven, 1992).  In 
school consultation, gender was associated with the likelihood of use of different power 
bases (Wilson, Erchul, and Raven, 2008).  Finally, having a power base available indicates 
neither that the agent will attempt to influence or prepare for the attempt nor does it mean 
that it will be an appropriate means of influence.  However, having power may increase the 
willingness to influence.  Kipnis (1972) found that individuals with more power attempted to 
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influence their workers more frequently in comparison to low power individuals.  Based on 
the finding, the author concluded that delegated power might encourage one to exert 
influence. Similarly, albeit in a different context, Lippitt et al. (1952) observed that attributed 
power was consistent with self-perceived power and recipients of attributed power made 
frequent influence attempts.  Therefore, it can be argued that the influencing agent 
deliberates over using particular bases of power before he or she finally prepares for the 
influencing attempt.  In other words, willingness to influence is the necessary intermediate 
step between the assessments of relative power bases and the preparation for influence 
attempts. 
While Raven (1992) clearly identified the role of cost-benefit implications on 
influence attempts, the variables and the relationship between the assessment of power and 
attempt to influence were not elucidated.  However, it may be argued that such variables may 
moderate the effect of power on willingness to influence for several reasons.  First, an 
influencing agent’s decision to invoke some power may be affected by individual 
preferences, situational attributes, or disadvantages and advantages of using power bases.  
For example, the agent, as argued by Getty (2006), may decide not to use a seemingly 
potential and available power base because of the potential for an adverse outcome.  
Additionally, Raven (1993) echoed the same possibility that the use of direct form of 
information power may result in a disastrous interpersonal relationship problem.  Second, if 
the agent has had previous experience, it may affect self-perception of power, perception of 
effectiveness, and cost of influence attempts (Raven, 1992).  In other words, experience may 
affect the decision to invoke power.  However, even in situations where the influencing agent 
does not have experience, it can be contended, the influencing agent – as a rational being – 
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will assume and prospectively assess the effects of such an influence attempt.  Furthermore, 
the use of different bases of power has been found to be associated with differential 
perceived effectiveness and outcomes (Raven, 1992; Wilson, Erchul, and Raven, 2008).  This 
evidence supports the argument that potential or perceived outcomes of influence attempts 
may affect one’s willingness to influence. 
Building on the findings of previous research as summarized in Table 1 and Raven’s 
(1992) power/interaction model of interpersonal influence, it can be posited that the 
assessment of power bases affects the agent’s willingness to influence and a number of 
relational, situational, and contingency variables moderate the relationship between power 
and willingness to influence.  For the sake of parsimony and relevance to this research, the 
relationship between pharmacist’s relative expert power and willingness to influence and the 
moderating effect of perceived impact on the interprofessional relationship quality were 
examined. 
Table 1: Select studies on power, use of power, and influence 
Authors Summary of findings 
Lippitt et al. (1952), Kipnis (1972) Power and influence attempts are positively related 
Erchul, Raven, and Whichard (2001), 
Koslowsky, Schwarzwald, and Ashuri 
(2001), Wilson, Erchul, and Raven (2008) 
Soft power bases are more effective and 
more likely to be used 
Raven (1992) Assessment of power bases is antecedent to 
influence attempt 
 
The extant literature on pharmacists’ influence on prescribing (as described in 
Chapter 2) supports the thought that the perception of inappropriateness of a prescription by a 
pharmacist is positively associated with the decision to influence prescribing.  However, in 
52 
 
case of off-label prescribing with inadequate evidence, the pharmacist may believe that the 
physician may have special reasons and knowledge or may possess adequate information 
supporting that choice of therapy.  Such a case can also be considered analogous to what 
Brown and Levinson (1987) described as ranking.  That is, asking a physician about the 
rationale of a prescription with low evidence may constitute a greater face threatening act to 
the physician than that with high evidence depending on the expertise of the physician.  As 
the ranking of the act increases, the communicator’s propensity to choose more polite 
communicative strategies increases with abstention from communication being the most 
polite strategy available (Lambert, 1995).  The propositions described below are based on the 
previously mentioned rationale and have been described in the proposed conceptual 
framework (Figure 1). 
P1: The pharmacist’s perceived relative expert power in relation to the physician is 
positively associated with the pharmacist’s willingness to influence off-label 
prescribing. 
P2: The perceived appropriateness of prescription medication is negatively 
associated with the pharmacist’s willingness to influence off-label prescribing. 
P3: The effect of the pharmacist’s relative expert power on the pharmacist’s 
willingness to influence off-label prescribing is moderated by the perceived 
appropriateness of prescription medication. 
P4 The effect of the pharmacist’s perceived relative expert power on willingness 
to influence off-label prescribing is moderated by the perceived impact on 
relationship quality with the physician as perceived by the pharmacist. 
 
VARIABLE OPERATIONALIZATION AND MEASUREMENT 
Dependent Variable 
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Willingness to influence 
Willingness to influence was the dependent variable in the study.  Willingness to 
influence was defined as the pharmacist’s willingness to initiate action with the physician in 
order to ensure rationale for an indication-based off-label prescription, perceived 
inappropriate by the pharmacist.  In other words, willingness to initiate action with the 
physician implies a willingness to intervene using rationality tactic.  Research focusing on 
influence has considered different tactics or elements of a complex array of influence forms 
that are used by the agent on the target to achieve the agent’s desired goals (Erez and Rim, 
1982; Kipnis, Schmidt, and Wilkinson, 1980; Schriesheim and Hinkin, 1990; Yukl and 
Falbe, 1991).  A synthesis of the influence literature revealed three categories of influence 
behavior: hard strategy (e.g., assertiveness), rational strategy (e.g., rationality; bargain), and 
soft strategy (e.g., friendliness; ingratiation; norms of reciprocity) (Kipnis and Schmidt, 
1985).  With a rational strategy, the agent appeals to or tries to invoke instrumental reasoning 
on the part of the target and presents himself/herself as knowledgeable and credible in order 
to evoke a positive response (Farmer et al., 1997).  For example, the influencing agent may 
offer a course of action that is supported with logic (evidence) and is consistent with the 
influence attempt in order to improve the expected utility or outcome that is important to the 
target of influence.  Although rationality is used more in cases of influence in the upward 
direction, it is viewed as socially acceptable for influence attempts in other directions as well 
(Yukl and Tracey, 1992) and has fewer costs associated with it than other influence tactics 
(Kipnis, Schmidt, and Wilkinson, 1980).  Therefore, it is appropriate to examine the use of 
rationality by pharmacists regardless of the fact that the pharmacist-physician relationship is 
not like a subordinate-superior relationship, rather a consultant-consultee dyad, although it is 
54 
 
widely believed that physicians enjoy more privilege than pharmacists in healthcare 
organizations.  Finally, whereas political norm structure may vary within an institution 
regarding what types of upward influence attempts are considered acceptable (Allen et al., 
1979), the use of reasons and logic seems to be almost universally accepted as an appropriate 
means of influence tactic (Farmer et al., 1997). 
To date, the influence typology offered by Kipnis, Schmidt, and Wilkinson (1980) 
has received substantial attention in psychology literature (Schriesheim and Hinkin, 1990; 
Yukl and Falbe, 1991; Yukl and Tracey, 1992).  Subsequently, Schriesheim and Hinkin 
(1990) presented an improved version of the typology and offered an empirically validated 
instrument.  This 18-item instrument was comprised of six dimensions (ingratiation, 
exchange of benefits, rationality, assertiveness, upward appeal, and coalition) of influence 
strategy.  The authors compared the 18-item scale with other potential shortened versions 
(e.g., a 27-item instrument) of the typology.  Although Schriesheim and Hinkin (1990) 
suggested that the 18-item scale had superiority over the other versions, for this study, the 
four items from 27-item scale classified under the rationality subscale were adapted in order 
to measure willingness to influence using rationality.  The four items consistently loaded 
under the rationality subscale in different studies (Schriesheim and Hinkin, 1990).  The 
subscale showed internal consistency of 0.74 and test-retest reliability and the correlation 
between the rationality subscale and social desirability was not significant (Schriesheim and 
Hinkin, 1990).  These four items were believed to capture adequately willingness to 
influence that may require one to use both verbal and written forms of communication that 
are common in pharmacist-physician communication within the hospital.  In addition, 
consistent with the measurement of other latent variables, a global measure of willingness to 
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intervene was added.  The participants were asked to indicate their level of agreement about 
their willingness to intervene and their willingness to use the rationality tactic using a 7-point 
scale where 1 = not at all willing and 7 = absolutely willing.  This response task followed 
immediately the exposure to the off-label prescription order scenario. 
Independent Variables  
Perceived relative expert power 
The pharmacist’s positive relative expert power was examined in the present study. 
Expert power is task oriented and decision-specific and depends on personal rather than 
organizational resources (Koslowsky, Schwarzwald, and Ashuri, 2001).  Expert power is 
accepted universally as a means of influence.  In previous studies in educational psychology 
and organizational attitudes, expert power has been found to be effective (Erchul, Raven, and 
Whichard, 2001; Koslowsky, Schwarzwald, and Ashuri, 2001; Raven 1992).  Arnston (2002) 
found that expert power was the most important determinant of the pharmacist’s influence on 
the P&T committee. 
Pharmacists provide professional services to physicians within their sphere of 
competence and expertise (pharmacotherapy).  Pharmacists collaborate with physicians in 
order to provide such services.  Therefore, it can be argued that pharmacist-physician dyad is 
similar to other dyadic relationships (e.g., school consultant-consultee) where power bases 
are utilized for influence attempts.  However, unlike other contexts, pharmacists and 
physicians share a domain of knowledge and skill.  As a result, conceptualization of 
pharmacist perception of relative expert power was considered appropriate and relevant in 
the context of the study.  The pharmacist’s relative positive expert power was defined as the 
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extent to which the pharmacist perceived to possess expertise and knowledge in a relevant 
area relative to that of the physician.  Pharmacist relative expert power was operationalized 
as perceived power differential between the pharmacist and the physician described in the 
study.  There were two experimental groups of pharmacists with high and low relative expert 
power.  The pharmacist’s relative expert power was believed to be high or power differential 
low when compared to a general practitioner with less knowledge and experience; the 
pharmacist’s relative expert power was believed to be low or power differential high when 
compared to a specialist physician with more knowledge and experience. 
Perceived appropriateness 
Physicians may prescribe medications off-label; however, it is expected that they will 
have a reasonable expectation of therapeutic success that is supported by sound scientific 
evidence (Henry, 1999).  Concerns for quality of care arise when evidence for use is not 
clear, is not sufficient, or is not well documented.  Such prescribing practice with some 
rationale but inadequate evidence, occasionally termed as innovative off-label prescribing, 
becomes challenging when prescribing is not considered clinical research (Ansani et al., 
2006).  In the context of clinical practice, indication and effectiveness are considered most 
important among different parameters of prescription medication appropriateness index 
(Samsa et al., 1994).  Effectiveness is closely related to safety and efficacy that are 
determined based on the strength and quality of scientific evidence.  For example, little or 
sparse empirical data, anecdotal evidence, or methodologically flawed study designs are 
considered poor quality and weak evidence.  Perceived appropriateness was operationalized 
as the extent to which the pharmacist perceived the medication as appropriate for the off-
label indication based on the strength and quality of evidence.  There were two categories – 
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“more” and “less” – of appropriateness of evidence supporting the off-label prescription.  
The more appropriate category (referred to in this project as off-label) had stronger and better 
quality evidence supporting the use of the drug for the specified off-label indication than the 
less appropriate category, termed in this project as experimentation. 
Moderating Variable 
Perceived impact on relationship quality 
It has been discussed that a rational agent considers multiple factors including 
consequential impact of influence before making a decision to influence.  Therefore, it can be 
argued that the pharmacist might weigh the impact of an influence attempt on the relationship 
with the physician before the pharmacist becomes willing to influence.  More specifically, 
the impact on relationship quality may become critical to such intent.  Developing, 
managing, and evaluating relationships within the context of dyadic transaction and 
voluntary participation has been studied well in the marketing literature.  More specifically, 
relationship quality (RQ) and relationship management have received a great deal of 
attention.  RQ has been empirically investigated in the domain of buyer-seller, distributor-
manufacturer, and service provider-customer relationships (Crosby, Evans, and Cowles, 
1990; Mohr and Speckman, 1994; Kumar, Scheer, and Steenkamp, 1995; Leuthesser, 1997; 
Dorsch, Swanson, and Kelly, 1998).  RQ is a higher-order multidimensional construct that 
consists of different positive relationship outcomes reflecting overall strengths of a 
relationship and the extent to which it fulfills the needs and expectations of the parties 
involved in the relationship (Smith, 1998).  However, there exists a lack of agreement on 
dimensions of RQ.  For example, Crosby, Evans, and Cowles, (1990) proposed two 
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dimensions of RQ: satisfaction and trust.  Smith (1998) conceptualized that RQ manifests, in 
the context of buyer-seller relationships, at least in three constructs namely, trust, 
commitment and satisfaction.  Drawing upon a large number of studies in relationship 
marketing, Roberts, Varki, and Brodie (2003) proposed that RQ in the domain of a customer 
relationship with a service providing firm had five dimensions: trust in provider’s integrity 
and benevolence, affective commitment, satisfaction and affective conflict and concluded 
that RQ predicted behavioral intention and subsumed service quality.  RQ is determined 
partly by key facets of relationship management (Smith, 1990).  Relationship management 
has been defined as the extent to which parties possess the behavioral tendency as well as 
orientation to actively cultivate and sustain close working relationships (Crosby, Evans, and 
Cowles, 1990).  Among various aspects of relationship management, communication has 
received consistent attention from researchers and has been observed to affect trust, 
commitment, and satisfaction (Anderson and Weitz, 1989; Anderson and Narus, 1990; 
Smith, 1990).  Other researchers have posited communication as key driver of or antecedent 
to RQ (Roberts, Varki, and Brodie, 2003).  Indeed, communication quality, assessed as 
formal and informal interaction between members of the dyad, has been considered a 
dimension of a scale that measures RQ from a firm’s perspective (Lages, Lages, and Lages, 
2005).  Finally, a study conducted with community pharmacists explored the nature of 
pharmacists’ perceived relationship quality with physicians within the context of 
pharmacists’ participation in interprofessional healthcare team (Dobson et al., 2006).  
Though not theoretically grounded, the relationship scale administered in the study had items 
that appeared to capture, at least in part, trust, satisfaction, communication, and commitment.  
In this study, perceived impact on relationship quality was defined as the extent to which the 
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pharmacist believed that the influence attempt would affect the pharmacist’s relationship 
with the physician with respect to trust, commitment, communication, satisfaction, and 
affective conflict.  Affective conflict was thought appropriate to measure because 
pharmacists might believe that the physician might perceive an influence attempt as 
encroachment on the domain of prescribing that is controlled by physicians.  Unfortunately, 
no single scale exists that adequately captured all the dimensions considered relevant for the 
current study.  Therefore, it was thought appropriate to adapt items from different studies that 
adequately captured all the relevant dimensions of RQ.  Items were adapted from Dobson et 
al. (2006), Roberts, Varki, and Brodie (2003), and Morgan and Hunt (1994). The scale from 
Dobson et al. (2006) has been applied in the context of physician-pharmacist relationship.  
Scales used in the three studies showed adequate reliability (>0.79) and factor loadings of the 
items under their intended factors were satisfactory.  Two items were included that measured 
attitudinal and affective commitment.  Three items measured communication (information 
sharing and recommendation providing).  For measuring trust, two items were used to 
measure credibility of pharmacist and his or her service.  Additionally, items measuring 
affective conflict (two) and satisfaction (two) were adapted from Roberts, Varki, and Brodie 
(2003).  Items measured the level of agreement with each statement about the perceived 
impact of influence attempt on relationship quality using a 7-point scale ranging from 1 
(strongly disagree) to 7 (strongly agree). 
Control Variables 
Control variables were related to other power bases and internal factors that might 
affect a pharmacist’s decision to act.  While discussing the power/interaction model, Raven 
(1992) proposed that motivational factors were important for exerting influence and choosing 
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influence strategies.  The motivational factor may be related to factors that satisfy internal 
needs.  As such, the control variables included in this study were pharmacists’ referent 
power, information power, and legitimate power of dependency, perceived responsibility, 
and attitude. 
Other bases of power 
In previous studies in educational psychology and organizational attitudes including 
the study of attitudes of nurse supervisors and nurses working in hospitals, the three power 
bases – direct information power, positive referent power, and legitimate power of 
dependency – along with expert power have been consistently grouped under the soft base of 
the soft/hard power dichotomy (Erchul, Raven, and Ray, 2001; Erchul, Raven, and 
Whichard, 2001; Koslowsky, Schwarzwald, and Ashuri, 2001; Raven, Schwarzwald, and 
Koslowsky, 1998).  Like expert power, these three bases of power were task relevant and 
sought compliance through personal resources rather than organizational resources 
(Koslowsky, Schwarzwald, and Ashuri, 2001).  In addition, expert power may be strongly 
related or share a common source with referent power and information power.  For example, 
the agent’s expertness may come from his/her experience, which may increase the target’s 
desire of identification with the agent.  Thus, experience may be associated with expert 
power and referent power.  A physician’s referent power may have a halo effect that may 
work against pharmacist’s expert power (French and Raven, 1968).  Similarly, the content of 
communication and acceptance of validity of the content are closely related – the former 
comes from information power and the latter comes from expert power.  The underlying 
factor for power of dependence may be the identification of the need for knowledge-driven 
assistance.  In sum, it can be argued, these three bases and expert power may operate 
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simultaneously or in tandem.  Additionally, Arnston (2002) concluded that in addition to 
expert power, information power and referent power were significant determinants of the 
pharmacist’s influence on the P&T committee.  Therefore, these three bases of power, 
measured as general attributes, were controlled such that the effect of expert power could be 
examined.  The pharmacist’s direct information power was defined as the extent to which 
he/she perceived to have access to and control over relevant information and had logical 
argument in relation to that of a physician.  The pharmacist’s legitimate power of dependence 
was operationalized as the extent the pharmacist perceived that a pharmacist had obligation 
to help a physician and a physician was dependent on the pharmacist.  The pharmacist’s 
perception of physician’s referent power was defined as the extent to which the pharmacist 
identified with a physician and had regard for the physician’s qualities. 
Although social power has been conceptualized not as the objective ability of the 
agent to influence but rather as the perception of the target of the potential ability of the 
agent, measures of pharmacists’ self-perceived power were considered in this study for 
several reasons.  First, self-perceived power generally reflects good measure of attributed 
power and was strongly and positively related with attributed power (Lippitt et al., 1952).  
Second, attribution may underrepresent actual power if the target is not aware of multiple 
sources of power that the agent may have but may not use or use effectively (Simon, 1953).  
Therefore, the agent may still intend to influence based on evaluation of power bases without 
the target being able to attribute until significant outcomes are achieved (El-Ansary and 
Stern, 1972).  Third, self-perceived power seems to be more relevant in the study of one’s 
willingness to influence.  Thus, assessing pharmacist self-perceived power was considered 
consistent with the goal of the proposed research. 
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To measure pharmacists’ self-perceived referent power and legitimate power of 
dependency, items were adapted from the Interpersonal Power Inventory (IPI), (Raven, 
Schwarzwald, and Koslowsky, 1998).  The instrument measures the expanded 
conceptualization of the power bases proposed by the power/interaction model of 
interpersonal influence (Raven, 1992).  The IPI appears to be a reliable instrument, with 
coefficient alpha ranging from 0.62 to 0.93 and coefficient alpha for both soft bases and hard 
bases greater than 0.80 (Erchul, Raven, and Ray, 2001; Schwarzwald, Koslowsky, and 
Allouf, 2005).  The instrument showed satisfactory convergent validity when analyzed with 
multiple approaches and superior discriminant validity (Koslowsky, Schwarzwald, and 
Ashuri, 2001).  The instrument was considered appropriate to examine pharmacist-physician 
power relationship because this relationship conceptually is similar to the school 
psychologist-teacher relationship as pharmacists and school psychologists provide 
consultation services to physicians and teachers respectively.  The operationalization of the 
information power subscale in the IPI was not applicable in the context.  Pharmacist’s 
relative information power was operationalized on the basis of the pharmacist’s perceived 
reasons for selection and access to and control over information in relation to that of a 
physician.  Five items were used measure information power.  As a result, a thirteen-item 
scale was designed to measure pharmacist direct information power, positive referent power, 
and legitimate power of dependency.  Pharmacists’ level of agreement about possessing 
those power traits were measured on a 7-point scale where 1 = strongly disagree and 7 = 
strongly agree. 
Perceived responsibility in off-label prescribing 
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The professional responsibility for ensuring safe and effective pharmacotherapy is 
shared by physicians and pharmacists.  In fact, there exists the need to maintain and extend 
interprofessional safeguards and oversight to ensure the delivery and quality of 
pharmaceutical care to patients (Rupp, DeYoung, and Schondelmeyer, 1992).  Pharmacists – 
due to a unique set of professional perspectives and skills – may make valuable contributions 
to appropriate off-label prescribing in cases when they perceive their responsibility in the 
process.  This argument stems from the relationship between responsibility and behavior.  
Role theory asserts that perceiving responsibility might imply action (Levinson, 1959).  Felt 
responsibility has received attention in the organizational psychology literature and has been 
associated with employees’ extra-role behavior (Pearce and Gregersen, 1991).  Krebs (1970) 
noted subjective feelings of responsibility were a precursor to altruistic acts.  Planas et al. 
(2005) found that community pharmacists perceived responsibility for drug therapy outcomes 
were associated with direct patient care behavior of the pharmacists.  In the one known study 
that investigated off-label prescribing in the hospital setting, pharmacists were reported to 
delegate the responsibility of issues related to off-label prescribing to the IRB (Ansani et al., 
2006) and may seek to justify their action or lack of action regarding the issue.  As a result, it 
is appropriate to posit that perceived professional responsibility plays a role upon one’s 
intention to act or behavior. 
Incorporating philosophical, moral, legal, and psychological components of 
responsibility, Schlenker et al. (1994) proposed the triangle model of responsibility (TMR) 
that provides an integrated and clear view of responsibility.  The TMR consists of three 
elements: prescriptions (e.g., rules, norms, expectations), events (e.g., actions and 
consequences), and identity images (roles, qualities, commitments) that can vary in relevance 
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or importance to the actor or the observer (Schlenker et al., 1994).  The TMR posits 
responsibility as the direct function of strengths of three links – prescription-event, event-
identity, and identity-prescription – as perceived by the person making evaluation.  The links 
describe if a clear set of prescriptions exist that have relevance to the actors and actors have 
resources to act and to control events or outcomes.  Researchers empirically tested the TMR 
in multiple studies and in different contexts including pharmacy and the relationships 
proposed in the model, in general, were supported (Schlenker et al., 1994; Britt, 1999; Planas 
et al., 2005).  Pharmacists’ perceived responsibility was operationally defined as the extent of 
responsibility perceived by the pharmacist in the evaluation of off-label prescribing.  The 
items to measure perceived responsibility were adapted from Schlenker et al. (1994).  The 
four items loaded under the responsibility factor and were found to have a theoretical basis.  
Perceived responsibility was measured on a 7-point scale ranging from 1 (strongly disagree) 
to 7 (strongly agree). 
Attitude 
Attitude toward indication-based off-label prescribing was measured was also 
included as a control variable.  Attitude has been defined as "a psychological tendency that is 
expressed by evaluating a particular entity with some degree of favor or disfavor" (Eagly and 
Chaiken, 1993, p. 1).  Therefore, it may be argued that favorable or unfavorable opinions 
about off-label prescribing may influence a pharmacist’s decision to act.  Generally, it has 
been found that an attitude has three components: cognitive, affective, and behavioral 
processes (Breckler, 1984).  However, attitudes can be formed or expressed primarily or 
exclusively based on any one of the three components or some combinatory of the three.  A 
cognitive-affective-behavioral analysis is considered as providing a convenient terminology 
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for analyzing differing aspects of attitude expressions (Eagly and Chaiken, 2007).  The 
cognitive component refers to beliefs or thoughts about an attitude object.  For example, a 
pharmacist may believe that off-label prescription is not safe.  The affective component 
refers to feelings or emotions associated with an attitude object.  For example, a pharmacist 
may express that they feel bad while dispensing an off-label prescription.  The behavioral 
component refers to past behaviors or behavioral intentions with respect to an attitude object.  
For example, a pharmacist may not want to get involved with off-label prescription fearing 
negative experience with an off-label prescription.  For this study, attitude was defined on the 
basis of the three components of attitude as described above.  Semantic differential has 
become a popular method for measurement of attitude (Himmelfarb, 1993) and the 
intercorrelations among the various bipolar adjectives are sufficiently high such that few 
bipolar scales result in sufficient reliability (Heise, 1970).  However, for the sake of 
appropriate operationalization and ease of interpretation, a 4-item, 7-point Likert-type scale 
(1=strongly disagree, 7=strongly agree) was used to measure attitude. 
Communication effectiveness 
Given the context of interprofessional interaction, the assessment of one’s own 
interpersonal communication disposition is important as it may affect the decision to act.  
Broadly speaking, communication competence reflects the impression or judgment about 
one’s own ability to manage interpersonal interaction (Rubin and Martin, 1994).  While the 
conceptualization of communication competence, generally considered a multidimensional 
construct, is debated, effectiveness and appropriateness are universally accepted as important 
dimensions (Spitzberg, 2003).  Appropriate communication implies whether the 
communication behavior meets specific situational and relational norms and obligations.  
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Effective communication, perceived by some scholars as necessary and sufficient condition 
for competence, is about accomplishing one’s goals or other desired objectives.  Evidence 
suggests that people perceive themselves competent when they were successful in achieving 
their goals (as cited in Canary and Spitzberg, 1987).  Thus, an effective communicator has 
the ability to handle conflict situations and solve issues in a cooperative manner (Rubin and 
Martin, 1994).  Communication effectiveness was measured with three items.  The items 
were drawn from the environmental control subscale of the Interpersonal Communication 
Competence Scale (Rubin and Martin, 1994).  While the scale has reported an acceptable 
reliability, the subscale has relatively less reliability.  However, the scale is appealing 
intuitively and has strong face validity (Spitzberg, 2003).  In addition, the developers have 
suggested that the subscale is an appropriate measure of communication effectiveness in 
compliance-gaining situations, consistent with its use in this context.  Pharmacists were 
asked to respond to the three items using a 7-point response format where 1 = never and 7 = 
always. 
Demographic variables 
In additional to the control variables, several demographic characteristics of the 
pharmacists in the sample were captured.  Time spent on clinical activities, educational 
background, gender, age, experience, and hospital type were collected in order to describe 
the study population. 
Research Design 
A 2X2 between-subjects design (Table 2) was used where pharmacist’s relative 
expert power measured as perceived power differential based on physician attributes and 
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appropriateness of the prescribed drug were the two factors.  Subjects were provided a 
scenario that offered one of two different physician profiles manipulating the perceived 
power differential between the pharmacist and physician. Additionally, the scenario 
described a prescribed medication that varied on the degree of appropriateness (off-label and 
experimentation) of use in the described medical conditions. 
Table 2: Research Design 
Between Subject Factors  
Degree of Appropriateness 
More 
(Off-label) 
Less 
(Experimentation) 
Power differential based 
on physician attributes  
High (Specialist) X11 X12 
Low (Generalist) X21 X22 
 
Experimental Procedure 
Four vignettes (Appendix A) were developed for use in this study.  Scenarios were 
designed to describe a situation where a hospitalized patient received an order for a 
medication (fluoxetine) from a physician.  The scenarios described the disease and relevant 
patient characteristics (e.g., age) that would be considered necessary for the evaluation of the 
patient’s treatment plan.  Each scenario described an order for a medication that could be 
categorized into one of the two groups on the basis of the degree of appropriateness: 
indication based off-label use with suitable evidence (off-label) and indication-based off-
label use with no/very minimal evidence (experimentation).  Such manipulation was based 
on the use of the medication in different off-label indications (diabetic neuropathy and 
fibromyalgia) and corresponding degree of evidence described in Drugdex®.  In other words, 
each pharmacist evaluated one of the combinations of medication order: 1) fluoxetine in 
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fibromyalgia (off-label) or 2) fluoxetine in diabetic neuropathy (experimentation).  An actual 
medication name was used in order to simulate a realistic situation.  In addition, using this 
approach would allow pharmacists the opportunity to verify indications for the drug in case 
they desired to do so as this was not a prohibited activity on the part of the respondents.  The 
order was written by a physician who practiced in the hospital.  However, all scenarios 
mentioned that the physician had been practicing in the hospital for the last two years in 
order to control for social distance (Lambert, 1995).  In the scenarios, pharmacist relative 
expert power was manipulated based on perceived power differential created by describing 
the physician’s attributes such as knowledge, experience, expertise, and practice specialty 
(specialist or generalist) of the physician (Table 3). 
Table 3: Physician profile: high power (specialist) vs. low power (generalist) 
 
 
 
 
 
 
 
The combined effect of all of these attributes was believed to create differences in 
perceptions of pharmacist’s relative expert power.  Following confirmation that the subject is 
practicing as pharmacist in a hospital, the subject was randomly assigned to one of the four 
groups that were formed based on the specialties of physicians and appropriateness of 
 
 
 
Dr. Smith is a general practitioner. Dr. 
Smith has 5 years of experience of 
clinical practice. 
 
Dr. Smith is a rheumatologist and 
highly recognized expert in the 
field of rheumatology. Dr. Smith is 
considered an extremely 
knowledgeable physician with 
extensive clinical experience. Dr. 
Smith has 20 years of experience of 
  
 Specialist Generalist 
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medication orders.  Subjects were asked to respond to the questions on information power, 
referent power, and legitimate power of dependence with reference to physicians in their 
hospital.  Subjects were also asked about their communication behavior and beliefs about and 
roles in off-label prescribing.  Then, a scenario was presented to the pharmacists.  Following 
exposure to the scenario, participants were asked to imagine that they were working as 
pharmacist in the situation and received the order for their approval.  Then respondent-
pharmacist was asked to respond to a battery of questions measuring the remaining variables 
of interest. 
Sampling Design 
The sample for this study was obtained from membership rolls of state affiliates of 
the American Society for Health-System Pharmacists (ASHP).  The ASHP state affiliates 
were contacted to seek access to their members.  The sampling frame of membership lists of 
participating affiliates can be considered, at least for practical purposes, a nationally 
representative database of pharmacists practicing in hospitals in the United States.  As noted 
earlier, the study aimed to examine the effect of pharmacists’ self-perceived power on 
willingness to influence inappropriate off-label prescribing.  As such, it is possible for any 
pharmacist to play the hypothesized role in off-label prescribing.  However, pharmacists 
involved in clinical activities and involvement in direct patient care activities are more likely 
to encounter such prescribing situations.  Moreover, a large number of hospitals in the U.S. 
follow a model of integrated pharmacy practice (Knapp, Blalock, and Black, 2001).  
Consistent with such practice, “clinical” pharmacy was operationalized based on time spent 
providing clinical pharmacy services and/or direct patient care services.  Bond et al. (2001) 
operationalized clinical pharmacists as those who spend 50% or more time providing clinical 
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services.  However, this definition appeared to be too restrictive for the current study.  
Existing evidence suggests that, on average, approximately 28% of pharmacists’ time is spent 
on clinical pharmacy services (Knapp, Blalock, and Black, 2001).  Pharmacists practicing in 
small hospitals may spend even less time on clinical services (Guerro, Nickman, and Bair, 
1990).  A recent survey reported that 14.1% and 37% hospitals had pharmacists spend less 
than 10% and 20% of their time monitoring medication therapy respectively (Pedersen, 
Schneider, and Scheckelhoff, 2007).  As a result, for this study, attention was paid to recruit 
an adequate number of pharmacists who spent 10% or more of their time on clinical 
pharmacy services or direct patient care.  This was thought to be consistent and appropriate 
with the goal of examining pharmacists’ perception of off-label prescribing.  Additionally, 
this study sought to include pharmacists practicing in community hospitals.  There are 
several reasons for examining off-label prescribing in community hospitals.  First, academic 
hospitals are likely to follow different working protocols than do community hospitals, as 
clinical trials are more likely to be conducted in academic medical centers (AMC) than they 
are in community hospitals.  As a result, pharmacists perceived roles and responsibilities may 
be different in AMCs compared to those in community hospitals.  Second, AMCs are likely 
to have an IRB that may be charged with handling off-label use of medications.  As a result, 
pharmacists have the opportunity (or responsibility) to delegate the issue to the IRB (Ansani 
et al., 2006b).  Finally, the number of community hospitals is larger than that of AMCs.  
Although anecdotal evidence suggests that off-label prescribing is as prevalent in community 
hospitals as in AMCs, how community hospitals address off-label prescribing has never been 
studied.  In addition, adequate representation of pharmacists who identified themselves as a 
clinical pharmacist was ensured. 
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Sample Size 
This study was powered to detect the effects of social power and appropriateness on 
the pharmacist’s willingness to act.  This approach was believed to be appropriate for 
pragmatic reasons (e.g., sample size) and primary research interest.  Using the ANCOVA 
option in G*Power (version 3) with an input of medium effect size and 80% power, it was 
determined that 179 usable final responses would be required in order to conduct analyses 
(approximately 45 per group).  However, it can be noted that this number of responses 
appears to be sufficient for analyses – including the analysis with the moderating variable – 
according to the rule-of-thumb for sample size suggested by Green (1991). 
SURVEY INSTRUMENT DESIGN 
A survey instrument (Appendix B) was designed to elicit responses on the variables 
that were studied.  The questionnaire began with a short description of off-label prescribing.  
Then items measuring information power, referent power, and legitimate power of 
dependence with reference to physicians were placed.  Items measuring pharmacist’s 
communication effectiveness, perceived responsibility in off-label prescribing, and attitude 
toward indication based off-label prescribing were placed afterward.  A scenario that 
described physician specialty and a medication order was presented.  Questions were 
developed and asked to collect information on 1) if they are willing to influence the 
physician for the drug perceived as prescribed off-label in an inappropriate manner, 2) 
perceived impact of influence attempt on relationship with physician, 3) self-perceived 
relative expert power, 4) appropriateness of use, and 5) demographic information.  The 
aforementioned order was followed to ensure appropriate and adequate utilization of 
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information and logical order.  For example, following the exposure to the scenario, 
questions on willingness to influence were asked to ensure maximum utilization of 
information presented in the scenario.  Then, questions on perceived impact on relationship 
quality and manipulation checks on self-perceived relative expert power and appropriateness 
of use were asked. 
Pretesting the Survey Instrument 
Before executing the survey and after obtaining the approval from The University of 
Mississippi’s IRB, questionnaires were pretested with Pharmacy Practice faculty, 
professional students, and graduate students in the Department of Pharmacy Administration 
at The University of Mississippi.  Based on feedback, necessary changes were made in order 
to improve interpretability and readability of the questionnaire.  Finally, two of the state 
affiliates (smaller affiliates) that agreed to facilitate the distribution of the survey to hospital 
pharmacists were requested to distribute the questionnaire to their members.  A group of 10 
hospital pharmacists who reported to be practicing in hospitals situated across a few states 
participated in the pretest.  Results of the pretest provided assurance that manipulations were 
working as expected.  Thus, pretesting questionnaires with the actual subjects improved the 
interpretability, hence reliability, of the questionnaire. 
Manipulation check 
A manipulation check was conducted to determine if the pharmacist’s perceived 
relative expert power manipulation was successful.  Effort was made to create a large 
difference in the perception of power of the physician.  To measure the manipulation of 
pharmacists’ self-perceived relative expert power, items from the expert power subscale from 
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the IPI (Raven, Schwarzwald, and Koslowsky, 1998) were adapted.  A 4-item scale 
(APPENDIX B, Q2.12) measured the manipulation of relative expert power on a scale of 1 
(strongly disagree) to 7 (strongly agree).  In addition, the manipulation of the perception of 
appropriateness of the prescription order was examined.  Perception of appropriateness of the 
medication order was examined using a two-item 7-point scale (1= not at all appropriate, 7= 
very appropriate) (APPENDIX B, Q2.13) for the medication order in the scenario. 
DATA COLLECTION 
A self-report survey methodology was used for data collection.  Data were collected 
using the Internet.  This method of data collection is convenient, efficient, and relatively 
inexpensive (Ileva, Baron, and Healey, 2002).  Moreover, it may be convenient for 
respondents to reply while at work.  The survey was administered using the online survey 
software provided by Qualtrics.  This study adopted a facilitated distribution approach for 
data collection.  First, an email cover letter (APPENDIX C) that contained the link to 
questionnaire was sent to the state affiliates who agreed to participate in the study (see 
APPENDIX D for the initial communication requesting access to members).  Then, the state 
affiliates were requested to resend the cover letter and link to their pharmacist members.  
Based on the geographic location of the completed responses, some of the ASHP state 
affiliates were sent a second request to distribute the survey invitation.  The state affiliates 
were request to distribute a reminder cover letter and the link to their membership 
approximately 7 days from the time it was reported that the first contact survey invitation 
was sent. 
DATA ANALYSIS 
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Data were analyzed using statistical software SPSS 17.  Descriptive statistics analyses 
were performed to examine the characteristics of the respondents.  Reliabilities (Cronbach’s 
alpha) of all the multi-item scales used in the study were examined.  Factor analysis on 
control power bases was conducted to examine whether the items loaded under the 
hypothesized factors.  Similar analyses were performed on the scales for measuring 
willingness to influence, perceived impact of influence attempt on relationship, perceived 
responsibility, and attitude. 
T-tests were performed to examine if relative expert power and appropriateness 
manipulations were successful.  The subjects in the specialist physician group were expected 
to rate power differential higher (low relative expert power of pharmacist) than those in the 
generalist group.  Hypotheses were tested using the ANCOVA analyses where relative expert 
power and appropriateness were independent variables.  In the ANCOVA analyses, 
perceived responsibility, attitude toward off-label prescribing, other three power bases, and 
communication effectiveness were covariates.  In addition to the main effects of the 
independent variables, interaction between relative expert power and appropriateness and 
that of expert power and impact of influence attempt on relationship quality were examined.  
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CHAPTER 4 
DATA ANALYSIS AND RESULTS 
As was described in Chapter 3, the sampling frame for the study came from the 
membership rolls of state affiliates of the American Society of Health-System Pharmacists 
(ASHP).  These membership rolls included practicing as well as nonpracticing (e.g., retirees) 
pharmacists.  Among practicing pharmacist members were those who reported presently to be 
working in hospitals, retail settings, long-term care, and other health care settings.  When 
contacted, 25 state affiliates agreed to forward the survey invitation to their membership.  
Because of pretest procedures, 23 affiliates were expected to distribute to its membership the 
survey invitation that contained a link to the Internet survey.  One state affiliate was reported to 
have posted the invitation request on its website only.  Of the remaining 22 affiliates that agreed 
to distribute the survey invitation, 17 reported to have distributed the survey.  As such, there 
remains a possibility that five of the affiliates that agreed to forward the request for participation 
failed to do so.  Consistent with the stated objectives of the study, only pharmacists reported to 
be currently working in the hospital setting were allowed to participate in the study.  Although 
the study was planned initially as an evaluation of nonacademic community hospitals, it became 
necessary to include responses from pharmacists practicing in academic hospitals as well.  
However, consistent with the objective of including pharmacists with at least some clinical 
duties, extra responses were collected above and beyond the predetermined target of 180 
responses.  A total of 238 respondents completed the survey and 29 participants provided partial 
responses such that their responses could be included in the study (information on demographics 
was entirely incomplete or partially complete).  Thus, 267 responses were available for analysis.  
Table 4 describes the number of respondents in each group. 
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Table 4: Number of Respondents in Experimental Groups 
Between Subject Factors  
Degree of Appropriateness 
More 
(Evidence-based 
Off-label) 
Less 
(Experimentation) 
 
Power differential based 
on physician attributes 
High (Specialist) 70 68 
Low (Generalist) 63 66 
 
As was mentioned in a previous chapter, the survey was conducted through facilitated 
distribution.  Although it is ideal to report response rate, it was not possible to do so because of 
non-availability of the number of participants who received an email contact along with the link 
to survey questionnaire (affiliates were not willing or not able to provide this information to the 
principal investigator).  In the interest of full disclosure, it can be noted here that a large number 
of potential respondents started the survey but did not complete it.  A total of 395 respondents 
were assigned to one of the four experimental groups by the questionnaire software (Qualtrics).  
However, over 100 potential respondents stopped their participation prior to being exposed to the 
experimental condition. 
SAMPLE DEMOGRAPHY 
Respondent Characteristics 
Table 5 summarizes the characteristics of the pharmacists included in the study.  Among 
respondents who provided demographic information, there were 126 male pharmacists and 134 
female pharmacists respectively.  The average age of the respondents was 44.18 years with a 
average hospital practice experience of 17.9 years.  One hundred and sixty two pharmacists 
reported to have earned a Pharm.D. degree and 50 pharmacist-respondents reported to hold at 
least one BPS specialization.  On average, respondent pharmacists spent 21.67% and 38.55% of 
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hours worked per week on distributive activities and clinical/ direct patient care services 
respectively.  Thus, respondents devote a substantial part of their weekly hours on clinical 
pharmacy-related services. 
Table 5: Respondents Demographics 
Characteristics Mean Std. err. N (%) 
 
Male 
   
126 (47.2) 
 
Age 
 
44.18 
 
0.77 
 
260 
 
Education* 
   
    B.S (Pharmacy)   94 (34.2) 
    Pharm.D.   116 (43.4) 
    B.S (Pharmacy) & BPS   11 (4.2) 
    Pharm.D. & BPS   46 (17.2) 
    Pharmacotherapy specialization among those with BPS   36 (72) 
 
Job title 
   
    Staff pharmacist   35 (13.4) 
    Clinical pharmacist   80(30.7) 
    Pharmacy manager/ director   63 (24.1) 
    Multiple descriptions   46 (17.6) 
    Other   24 (9.2) 
 
Experience 
   
    Present hospital 11.49 0.64 249 
    Total hospital practice 17.89 0.77 250 
 
Average percentage of time spent per week 
   
    Distributive  21.67 1.70 250 
    Clinical/ direct patient care 38.55 1.95 249 
    Administrative 29.99 2.13 250 
    Other 9.19 1.21 247 
* Categories are not mutually exclusive 
 
Respondents were asked also to describe their current job; pharmacists could identify themselves 
as having multiple job titles.  One hundred and twenty four pharmacists identified themselves as 
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clinical pharmacists, 55 as staff pharmacists, 31 as pharmacy managers, 45 as pharmacy 
directors, 10 as consultant pharmacists, and 38 as other (part-time retail, residency, faculty, 
clinical faculty, informatics).  However, a majority (nearly 70%) of pharmacists who exclusively 
chose to be identified as other were devoting 20% or more time to direct patient care or clinical 
services.  As described in Table 5, a large number of pharmacists identified themselves solely as 
a clinical pharmacist.  Altogether, respondents represent a group, which is composed of 
pharmacists who follow an integrated pharmacy practice model (Knapp, Blalock, and Black, 
2001), pharmacists with exclusively clinical duties, and administrators who may have better 
ideas about hospital policies. 
Hospital Characteristics 
Information about the hospitals where respondents currently practice was collected 
(Table 6).  Hospitals were distributed across all four geographic regions (as classified by the U.S. 
Census Bureau) with the largest group (41.6%) of them being located in the South.  Over 50% of 
these hospitals were described as private not-for-profit community hospitals.  Additionally, a 
majority of the hospitals in which respondent pharmacists are employed have an IRB but no 
policy regarding off-label prescribing. 
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Table 6: Respondents’ Hospital Characteristics 
Characteristics N % 
 
Geographic region 
  
 Northeast 82 30.7 
 Midwest 25 9.4 
 South 111 41.6 
 West 30 11.2 
TOTAL 248 92.9 
 
Hospital is an academic medical center 
 
111 
 
41.6 
TOTAL 250 93.6 
 
Type of ownership 
  
 Private community hospital (not-for-profit) 136 50.9 
 Private community hospital (for-profit) 21 7.9 
 Public community hospital 24 9.0 
 Federal hospital 11 4.1 
 University hospital 49 18.4 
Other 9 3.4 
TOTAL 250 93.6 
 
Hospital with an IRB 
 
208 
 
77.9 
TOTAL 249 93.3 
 
Hospital with policy on off-label prescribing 
 
110 
 
41.2 
TOTAL 250 93.6 
N.B., total represents number of participants responded to the question. 
 
Group Comparisons on Characteristics 
As was described in Chapter 3, study participants were randomly assigned to one of the 
four experimental groups.  Therefore, the groups can be expected to be similar with regard to 
important demographic characteristics.  Because attrition rate was high before and after group 
assignment, groups were compared to determine if differences between the experimental groups 
occurred.  ANOVA analysis was performed to examine if groups differed in the distribution of 
age, pharmacy practice experience, and clinical duties.  No differences were found among the 
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experimental groups on these characteristics; however, a difference (p=0.014) was found among 
the groups when experience in their present hospital was evaluated.  Pharmacists in the 
generalist-low appropriate group showed the highest experience (mean=13.7 years, s.d.=11.4) in 
present hospital, followed by those in the specialist-high appropriate group.  These two groups 
also showed the largest variance in response patterns.  The lowest mean was observed for the 
generalist-high appropriate (mean=9.01 years, s.d.=8.8) group, which is also the smallest cell.  
Considering unequal variances and cell sizes, experiences in present hospital did not appear to be 
significantly different as revealed by post-hoc comparisons (Dunnett T3 (p=0.07); Games-
Howell (p=0.06)).  It can also be argued that although experience in present hospital may give 
familiarity with policy and influence working relationships, there may be a ceiling effect; 
whereas total experience may play a role in perceiving expert power differential – a variable of 
principal interest.  Therefore, it was believed that a difference in experience in their present 
hospital would not affect significantly the results from subsequent analyses.  Similarly, cross 
tabulations (chi-square) were run to determine differences between groups in the distribution of 
gender, job title, hospital ownership status, AMCs, hospital type, existence of IRB and off-label 
policy, and education.  No significant differences with respect to these variables were observed 
among experimental groups.  Although number of subjects having any BPS specialization was 
significantly (p<0.05) low in the generalist low appropriate group, no such difference was 
observed on having a pharmacotherapy specialization, which represents the largest category 
(>90%) of BPS in the respondents participating in the survey.  Thus, it was believed that the 
experimental groups were similar.  
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Anomalies in Responses 
Before analyzing data for inferential purposes, inspection of response patterns or 
‘consistency checking’ (Singleton and Straits, 2005, p. 478) was required.  In other words, an 
evaluation was undertaken in order to determine if responses to questions are intuitive or are 
related to those of other questions in a reasonable manner.  Each case was thoroughly inspected 
for each variable and each dubious case was flagged.  Six such cases were identified and reasons 
are presented in Table 7 along with any action taken.  In addition, response patterns on item 8 
through item 11 of the impact on relationship quality scale (IRQ) were examined.  The purpose 
of the scale was to examine perceived negative outcomes associated with a pharmacist’s action.  
Responses on IRQ were recorded on a 7-point scale (1=not at all; 7=absolutely).  It can be noted 
here that if either of item 8 (angry) or item 9 (annoyed) is greater than 4 then both item 10 
(content) and item 11 (happy) should be less than 4 and vice versa.  However, responses on all 
these items can be on the lower side of the scale simultaneously, meaning that the respondent is 
not much concerned or concerned at all.  Based on the argument, 23 cases, which include 4 cases 
already flagged, were identified for which responses on IRQ were considered incompatible and 
reclassified as missing data (Singleton and Straits, 2005). 
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Table 7: Inconsistency in Responses 
 
Questions/
Scale Item  
Case # Reasons/ Action 
Items from 
multiple 
variables 
31 All 1s (willingness to influence < -1.96 of standardized values of the 
DV) - flagged 
76 Q2.5.1 onwards all are 5s, Q2.3.5 and q2.3.8 (both are 4), Q2.3.6, 
Q2.4.2, and Q2.4.3 (all are 6s), q2.4.1 is 3, and the rest are 5s - flagged 
100 All 7s except Q2.4.1 to Q2.4.3 all of which are 4s - flagged 
173 Q2.3.4 is 4 and Q2.5.1 onwards all are 4s and the rest are 5s 
225 All 7s except Q2.3.5 that is 6 - flagged 
232 All 7s- flagged 
IRQ 
 
*Bold 
values are 
incompati
ble in 
pairs 
(1sttwo vs. 
2nd two) 
23, 65 6, 6, 6, 6– recoded as missing 
43 6, 5, 6, 6– recoded as missing 
71 6, 6, 5, 4– recoded as missing 
82 3, 6, 5, 4– recoded as missing 
89 5, 5, 5, 5– recoded as missing 
107 3, 5, 5, 5– recoded as missing 
109 4, 5, 5, 5– recoded as missing 
114 4, 5, 6, 6– recoded as missing 
123 5, 5, 4, 5– recoded as missing 
152 5, 5, 3, 5– recoded as missing 
162 1, 5, 4, 5– recoded as missing 
206 6, 7, 5, 3– recoded as missing 
222 2, 5, 5, 4– recoded as missing 
226 4, 5, 6, 5– recoded as missing 
246 2, 6, 6, 6– recoded as missing 
256 4, 5, 4, 5– recoded as missing 
 
Manipulation Checks 
Pretest results provided an initial indication that the manipulation of the independent 
variables (expert power differential and appropriateness) were working as expected.  However, 
due to an inadequate number of responses available in the pretest, it was not possible to conduct 
statistical analyses to verify that assertion.  To ensure that the experimental manipulation was 
working as conceived, several statistical tests (t-tests) were performed.  Respondents were asked 
if they believed that the physician described in the vignette had more expert power – measured 
by average of responses on a four-item 7-point scale – than did the respondent.  It can be noted 
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here that the four-item measure loaded under a single factor as conceptualized and reliability of 
the scale was acceptable (Cronbach’s alpha = 0.877).  The results (Table 8) that excluded flagged 
cases showed that pharmacists assigned to the specialist physician group rated the physician’s 
relative expert power significantly higher (p<0.001) as compared to participants in the generalist 
group.  However, in general, pharmacists in both groups rather somewhat disagreed on a great 
power differential between pharmacists and the physicians described in the study as indicated by 
the average ratings that are less than 4 (4=’neutral’).  This result may be a reflection of the 
clinical acumen of the pharmacists in the sample.  A large number of respondents held advanced 
practice degrees (e.g., Pharm.D.) and spent a significant portion of their work-related activities 
on clinical functions. 
In addition to evaluating power differences, pharmacist respondents were asked about the 
appropriateness of the medication in the disease condition as described in the scenario.  
Appropriateness was measured as mean of two items.  As expected, respondents in the low 
appropriate group rated the off-label use significantly (p<0.001) less appropriate than did the 
pharmacists in the high appropriate group.  The results for both manipulations did not change 
when either all cases were included or all cases identified in Table 7 were excluded. 
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Table 8: Manipulation Checks 
Group N Mean 
(Std.err.) 
Sig (p) 
Relative expert power of physician Specialist 135 3.68 (0.13) <0.001 
Generalist 126 3.12 (0.09) 
Appropriateness Evidence-based (high) 131 5.29 (0.10) <0.001 
Experimentation (low) 130 3.55 (0.11) 
N.B., higher number means higher power of physician or appropriateness; flagged cases 
 
 
EXAMINATION OF MEASUREMENT SCALES 
Although scale items of almost all variables appear in the published literature, the 
population and the context of this study were different from those studies.  As suggested by 
Churchill (1979), factor analyses (principal axis factoring (PAF)) were performed on the 
variables measured by scale items to determine if they loaded on the factor as conceptualized.  
Reliabilities (internal consistency) of multi-item scales were then estimated. 
Dependent Variable 
The dependent variable (DV), willingness to influence, was measured by five items.  The 
descriptive statistics of the DV have been presented in Table 9.  The distribution of the DV was 
negatively skewed such that the mean values of each group were above 5 on a 7-point scale. 
However, 95% of values lay between ±1.96 of standard deviation.  
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Table 9: Descriptive Statistics of Willingness to Influence (N=267) 
 
Statistic Value 
Overall scale mean and std. error 5.54 (0.082) 
Skewness -1.072 
Kurtosis 1.085 
Between-group homogeneity of variance – 
Brown-Forsythe test (p) 0.302 
Reliability (Cronbach’s alpha) 0.929 
N.B., Estimates include cases that are flagged. 
 
Considerable debate exists over appropriateness of factor analysis model in a specific 
context (Hair et al., 2006).  The scale measuring the DV had already been applied (Schriesheim 
and Hinkin, 1990) and its factor structure was confirmed.  Thus, the objective of factor analysis 
here was to reassess the latent dimension in the context of the study; common factor analysis was 
thought appropriate as suggested by Hair et al. (2006).  The factor analysis (PAF) of the five 
items of the DV (loadings >0.8) loaded strongly under a single factor as expected.  Reliability 
(Cronbach’s alpha) was 0.925 excluding six flagged cases.  The reliability estimate did not 
change meaningfully when those cases were included.  All inter-item correlations were 
significant (p<0.01) and ranged from 0.627 to 0.801.  All item-to-total correlations were 0.767 or 
greater.  It was concluded that the willingness to influence scale was reliable and was suitable for 
use in subsequent analyses (Hair et al., 2006; Peter, 1979). 
In addition to willingness to influence, the survey instrument contained a three-item scale 
to measure a distinct, yet related, concept, likelihood to act.  The scale appeared to be reliable 
(Cronbach’s alpha 0.863) with all item-to-total correlations greater than 0.60.  Although the 
measure of willingness to influence was adapted from past research and well validated, 
considering different context and population construct validity it was examined further.  If the 
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measure is valid, it should correlate with a measure of a theoretically-related concept (Singleton 
and Straits, 2005).  The correlation between likelihood to act and willingness to influence was 
0.569, which is significant at the 0.01 level.  However, pairwise correlations of the variables 
(items) of the willingness to influence scale with the variables of the likelihood to act scales were 
lesser than correlations among within-scale variables of willingness to influence.  Thus, the 
measure of willingness to influence provided evidence of construct validity (Churchill, 1979; 
Churchill and Surprenant, 1982). 
Covariates and Moderator 
While developing the instrument (IPI) Raven, Schwarzwald, and Koslowsky (1998) used 
Principal Component Analysis.  However, in this study common factor analyses (PAF) of the 
covariate power variables were performed to examine the factor structures of the IPI because of 
the argument (i.e., reassessing factor structure) presented above and results are displayed in 
Table 10.  The items measuring power of dependence loaded strongly under a factor without any 
cross-loadings that are greater than 0.3.  Referent power items were not good as evidenced from 
poor loadings (less than 0.5) except for one item with a factor loading greater than 0.7.  
Surprisingly, information power items loaded under two factors.  Three items loaded strongly on 
a single factor with no large cross-loadings.  In the present analysis, percentage of variance 
extracted by the first factor was slightly higher (10.61% vs. 9.49%) than the second factor.  
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As was described earlier in the text, the moderating variable IRQ contained some 
responses that could be considered incompatible.  As such, an additional analysis was undertaken 
where these cases were classified as missing.  As opposed to the a-priori conceptualization, IRQ 
emerged as two factors.  First, nine items loaded on a single factor while two items loaded under 
another factor with a small cross-loading of one item (loaded more heavily under the first factor).  
It can be noted that the first factor extracted a very large amount of variance (67.68%) while the 
Table 10: Factor Analysis of the Covariates and Moderator with Varimax Rotation 
 
Scale Item 
 
Factor 
1 2 3 4 5 6 
Power of 
dependence 
Q.2.3.1 0.784      
Q.2.3.2 0.869      
Q.2.3.3 0.551      
Q.2.3.4 0.793      
Referent power Q.2.3.5       
Q.2.3.6    0.322   
Q.2.3.7       
Q.2.3.8    0.770   
Informational power Q.2.3.9   0.714    
Q.2.3.10*  0.676     
Q.2.3.11*  0.893     
Q.2.3.12*  0.722     
Q.2.3.13   0.707    
IRQ** Q.2.11.1     0.930  
Q.2.11.2     0.899  
Q.2.11.3     0.884  
Q.2.11.4     0.934  
Q.2.11.5     0.940  
Q.2.11.6     0.890  
Q.2.11.7     0.930  
Q.2.11.8     0.754  
Q.2.11.9     0.732  
Q.2.11.10*     0.447 0.783 
Q.2.11.11*      0.825 
 
N.B. * items are reverse coded. Only factor loadings > 0.3 in absolute value were 
presented.  ** Run on data that excluded incompatible responses. All estimates excluded 
flagged cases. 
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second factor extracted only 13.15% of variance.  Hair et al. (2006) suggests that a solution that 
explains 60% of the total variance can be considered satisfactory in some cases.  While 
consistent with a-priori conceptualization, the one factor solution was believed to be appropriate 
as it would capture variance sufficiently and be parsimonious as well.  In addition, dropping the 
last two items may alleviate the response pattern issues as described previously.  Factor analysis 
was run again on the abbreviated IRQ scale and the single-solution factor extracted 80.55% of 
variance.  It should be noted that the results did not change meaningfully when all cases were 
considered. 
After examining the factor structures of the various measures, reliability estimates were 
examined.  The results are presented in Table 11.  The reliability estimate of the power of 
dependence scale was 0.867.  All inter-item correlations ranged from 0.411 to 0.814 and item-
total correlations from 0.518 to 0.844.  The reliability estimate of referent power was poor 
(0.394) and thus not acceptable (Hair et al., 2006).  In addition, inter-item correlations (<0.3) and 
item-total correlations (<0.4) were not high.  Thus, it is concluded the scale measuring referent 
power was not reliable and was not included in subsequent analyses.  When five items were 
considered together, the information power scale had a reliability of 0.679 which is not 
satisfactory (Hair et al., 2006).  However, two items had low item-to-total correlations of 0.207 
and 0.329.  Moreover, these same two items loaded under a different factor when factor analysis 
was performed.  The item-total correlations for the remaining three items were between 0.472 
and 0.62.  While deleting the item with the lowest item-total correlation would improve the 
scale’s reliability (0.723), the other item still showed poor item-total correlation (0.162).  
Although it may be tempting to conclude that the information power measure has an underlying 
two-factor structure, the original conceptualization does not support this interpretation (Raven, 
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Schwarzwald, and Koslowsky, 1998).  Moreover, unidimensionality should be ensured before 
reliability is established (Gerbing and Anderson, 1988).  It can be noted here that although the 
two items causing concerns possessed face validity (they appear very close to what is potentially 
captured by expert power (e.g., physician has better explanation)), past research has shown 
empirically that expert power and information power are correlated (Raven, Schwarzwald, and 
Koslowsky, 1998).  In that case, retaining the two items may remove some variance from expert 
power that it jointly shares with the DV and information power and reduce the efficiency of 
ANCOVA analysis (Miller and Chapman, 2001).  On the other hand, if the three-item 
information power scale is adopted, the reliability estimate becomes 0.825.  Having a measure 
with high reliability may also serve to satisfy – at least, partially – an assumption of ANCOVA 
(i.e., covariates are measured without error).  Therefore, for the sake of parsimony and consistent 
with the theory and measurement practice, information power was measured as a single factor 
with three items.  
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Table 11: Reliability Estimates of the Covariates and Moderator 
 
 
Scale Items N Cronbach’s α Mean (s.d.) 
Power      
Power of 
dependence Q.2.3.1, Q.2.3.2, Q.2.3.3, Q.2.3.4 261 0.867 
5.082 
(0.669) 
Referent 
power Q.2.3.5, Q.2.3.6, Q.2.3.7, Q.2.3.8 261 0.394 
4.045 
(1.228) 
Information 
power Q.2.3.10*, Q.2.3.11*, Q.2.3.12* 261 0.825 
3.410 
(0.210) 
Communication 
effectiveness Q.2.4.1, Q.2.4.2, Q.2.4.3 261 0.685 
5.289 
(0.224) 
Responsibility Q.2.5.1, Q.2.5.2, Q.2.5.3, Q.2.5.4 261 0.909 4.963 (0.277) 
Attitude Q.2.6.1, Q.2.6.2, Q.2.6.3, Q.2.6.4 261 0.838 4.863 (0.682) 
IRQ 
Q.2.11.1, Q.2.11.2, Q.2.11.3, 
Q.2.11.4, Q.2.11.5, Q.2.11.6, 
Q.2.11.7, Q.2.11.8, Q.2.11.9, 
Q.2.11.10*, Q.2.11.11* 
242 0.967 2.359 (0.195) 
* Items recoded because of reverse coding   
 
The reliability of the communication effectiveness measure was 0.685 and all inter-item 
and item-total correlations were larger than 0.30.  The four-item responsibility scale showed very 
good reliability and all inter-item and item-total correlations were larger than 0.60.  Similarly, 
the attitude measure was found to be very reliable.  The reliability of estimate of IRQ (shortened) 
was calculated.  Cronbach’s alpha of the scale was 0.967.  None of the inter-item correlations 
were less than 0.55 while all item-total correlations stood above 0.70.  The scale appeared to be 
reliable. 
EXAMINATION OF PROPOSITIONS 
As proposed in Chapter 3, the propositions were examined using ANCOVA.  It can be 
noted again that although referent power was originally proposed as a covariate, it was not 
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included in the analysis because of inadequate reliability of the measure.  Before proceeding with 
ANCOVA analysis, an examination of the assumptions of ANCOVA was undertaken. 
Assumptions of ANCOVA 
While performing ANCOVA analysis it expected that covariates were correlated with the 
DV such that they account for variance in the DV that is otherwise unexplained.  To examine 
such relationships, bivariate correlations were estimated (Table 12).  All correlations between the 
covariates and willingness to influence were significant (p<0.01) and appeared in the direction 
conceptualized.  All correlations except one among the covariates were also significant (p<0.01).  
However, these correlations were, at best, moderate (Myers and Well, 2003).  Thus, it can be 
expected that multicollinearity should not be an issue. 
 
A critical assumption of ANCOVA is homogeneity of regression slopes among treatment 
groups.  This assumption was evaluated by performing ANOVA on the DV where significance 
of all group by covariate interactions were examined.  The group variable was a categorical 
variable that represented four experimental groups.  None of the interactions were significant at 
the 0.05 level, thus, the relationships between the covariates and the DV appeared similar across 
all treatment groups.  Concerning independence of covariates and IVs, treatment affecting 
Table 12: Correlations among Covariates and DV 
 
 Pow - dep Pow -info Com. effect Respon Attitude 
Willingness to influ 0.417* -0.139* 0.356* 0.320* 0.179* 
Pow - dep  -0.402* 0.313* 0.376* 0.190* 
Pow - info   -0.202* -0.254* -0.012 
Com. effect    0.213* 0.228* 
Respon     0.225* 
 
*Correlation is significant at the 0.01 level (2-tailed). 
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covariate was not a concern because the covariates were measured before the experimental 
manipulation was introduced. 
There were only four extreme cases of scores on the DV considering all groups 
individually.  The distribution of the DV in each group was negatively skewed.  Responses in the 
specialist-high appropriate group showed the highest skewness, followed by that of the 
specialist-low appropriate group.  The distributions of the DV in each group showed departure 
from normality (Shapiro-Wilk test p-value <0.05); however, departure from normality does not 
have serious consequences on the results of ANCOVA as long as sample sizes are large and 
equal and in the case of the current study, cell sizes vary very little (Myers and Well, 2003). 
Results of ANCOVA Analysis 
The ANCOVA results are presented in Table 13.  The results revealed that two 
covariates, power of dependency and pharmacist’s perceived responsibility, were significantly 
(p<0.05) related with a pharmacist’s willingness to influence off-label prescribing.  However, 
interpretation of main effects may not be appropriate in presence of significant interactions 
(Meyers and Well, 2003).  Following this argument, the interactions were analyzed and 
discussed first.  The results shows that the interaction between power differential and IRQ is 
significant (F(1, 230)=4.693; p=0.031).  In other words, the effect of pharmacist’s perceived 
relative expert power on willingness to influence prescribing is moderated by pharmacist’s 
perceived negative impact on relationship quality with physician.  This provides evidence in 
support of Proposition 4 (the effect of pharmacist’s relative expert power on pharmacist’s 
willingness to influence prescribing would be moderated by perceived appropriateness of off-
label prescription medication).  However, this result does not support Proposition 3 (F(1, 
230)=3.489, p=0.063) at the a-priori significance level of 0.05.  Interestingly, the interaction 
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between IRQ and appropriateness emerged to be strongly significant (F(1, 230)=9.541, p=0.002).  
The effect of perceived appropriateness on pharmacist’s willingness to influence is moderated by 
perceived impact on relationship quality.  It was proposed that perceived appropriateness of 
prescription medication would be negatively associated with pharmacist’s willingness to 
influence prescribing.  The result revealed a significant (F(1, 230)=8.632, p=0.004) main effect 
of appropriateness.  Estimated marginal means (Table 14) of a pharmacist’s willingness to 
influence in circumstances where the prescription is perceived less appropriate is greater than in 
situations where the prescription is perceived more appropriate (off-label but with more 
evidence).  Thus, Proposition 2 was supported, although the interpretation of this main effect 
deserves caution in presence of a significant interaction.  
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Table 13: Tests of Between-Subjects Effects 
 
Dependent Variable: Willingness to influence 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. Proposition 
Corrected Model 151.579a 11 13.780 12.462 <0.001  
Intercept 19.350 1 19.350 17.500 <0.001  
Power differential 4.353 1 4.353 3.937 0.048 P1 
Appropriateness 9.545 1 9.545 8.632 0.004 P2 
IRQ 26.463 1 26.463 23.932 <0.001  
Power dependency 20.974 1 20.974 18.968 <0.001  
Power information 1.062 1 1.062 .960 0.328  
Communication. Effectiveness 2.760 1 2.760 2.496 0.116  
Attitude  .003 1 .003 .002 0.962  
Responsibility 10.584 1 10.584 9.572 0.002  
Power diff * Appropriateness 3.858 1 3.858 3.489 0.063 P3 
Power diff *IRQ 5.189 1 5.189 4.693 0.031 P4 
Appropriateness * IRQ 10.549 1 10.549 9.541 0.002  
Error 254.322 230 1.106    
Total 7930.200 242     
Corrected Total 405.901 241     
a. R Squared = 0.373 (Adjusted R Squared = 0.343); b. Computed using alpha = 0.05 
*Data excluded incompatible and flagged cases. 
The effect of expert power differential between the pharmacist and the prescriber was 
examined.  It was proposed that pharmacist’s perceived relative expert power in relation to 
physician would be positively associated with pharmacist’s willingness to influence off-label 
prescribing.  Expert power differential did have a significant (F(1, 230)=3.937, p=0.048) 
relationship with pharmacist’s willingness to influence.  Surprisingly, direction of association 
appeared different from what was proposed.  The estimated marginal means for willingness to 
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influence was lower for the low power differential (general physician) group as opposed to that 
for the high power differential (specialist) group.  Thus, although Proposition 1 was supported 
partially, it should be cautiously interpreted as noted above. 
 
The aforementioned results revealed significant interactions as well as main effects; 
especially noteworthy was the interplay between three IVs.  Differences in opinion exist as to 
when one should look at simple effects.  Following the recommendation of Myers and Well 
(2003), simple effects that were determined to have theoretical interest and practical utility were 
analyzed.  In order to understand a complex set of effects that seem to be driven strongly by IRQ, 
separate ANCOVA analyses were undertaken within the two levels of expert power differential 
and the two levels of appropriateness.  It should be noted here that all of these tests can be 
considered conservative (less powered) because error mean squares are bigger than that of the 
full model.  As was mentioned previously (Table 13), it appeared that IRQ might play a strong 
role in pharmacists’ willingness to influence.  To interpret the effect better, IRQ was 
dichotomized on the median value of two so that interactions involving IRQ can be plotted.  
Figures 1 and Figures 2 describe interaction plots that involve IRQ.  These interactions showed 
Table 14: Estimated Marginal Means for Main Effects 
 
Variable Group Mean Std. 
Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Degree of 
appropriateness 
Experiment/low 5.577a 0.099 5.381 5.772 
off-label/high 5.535a 0.094 5.349 5.721 
Expert power 
differential 
GP-low 5.550a 0.098 5.357 5.742 
Specialist-high 5.562a 0.096 5.374 5.750 
a. Covariates appearing in the model are evaluated at the following values: power of 
dependency = 5.0816, power of information = 3.4339, comm. effect = 5.2920, attitude = 
4.8419, responsibility = 4.9607, IRQ = 2.3590.   * N = 242. 
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what Kleinbaum et al. (2008) called the same direction effect and both were significant at the 
0.05 level.  Although insignificant (p=0.063), the interaction (Figure 3) between power and 
appropriateness showed reverse direction (Kleinbaum et al., 2008).  Within the specialist group, 
the main effects of appropriateness (p=0.045) and IRQ (p<0.001) as well as interaction were 
significant (p=0.004).  However, within the generalist group neither the interaction (p=0.171) 
between appropriateness and IRQ nor the main effects of appropriateness (p=0.056) and IRQ 
(p=0.118) were significant.  When the simple effects within different appropriateness levels were 
analyzed, none of the main effects or interaction between expert power differential and IRQ were 
significant at p=0.05 level in the high appropriate group.  In contrast, within the low appropriate 
group, the interaction between IRQ and power differential was significant (p=0.029).  While the 
main effect of power differential was not significant (p=0.144), that of IRQ was significant 
(p=0.029).  It should be noted here that none of the simple comparisons with Bonferroni 
adjustments under these within-group analyses were significant at the 0.05 level. 
Overall, the model was significant and 34.3% variance (adjusted) was explained by the 
model.  The variables of interest contributed substantially to the total explained variance in the 
model.  Among the effects, IRQ stood above any other variables in terms of its ability to explain 
variability of willingness to influence. 
Post-hoc Analyses to Examine the Sensitivity of the Results 
Initially, it was planned that population would consist of pharmacists solely from 
nonacademic community hospitals.  However, in the interest of pragmatism, data collection 
included pharmacists employed by academic medical centers (AMCs).  ANCOVA analysis was 
performed to determine if there is any difference in effects based on type of hospital (AMC vs. 
non-AMC).  A main effect term of dichotomous hospital type and three interactions with power 
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differential, appropriateness, and IRQ were added to the full model that was used to examine the 
propositions.  Neither the addition of new terms changed the pattern of results nor were any of 
them significant.  Indeed, the result from the new model with all interaction terms replicated the 
original findings.  Thus, hospital type (AMC vs. non-AMC) does not appear to affect 
pharmacist’s willingness to influence off-label prescribing.  It was expected that nonacademic 
hospitals would be less likely to have an IRB, which may influence the manner in which off-
label prescribing is handled within the hospital (Ansani et al., 2006).  However, because only a 
small percentage (<20%) of hospitals reported not having an IRB, statistical analysis may not 
show reliable estimates.  Instead, the effect of existence of policy regarding off-label prescribing 
in their hospital was examined by adding to the original model a new main effect term for policy 
and its interaction terms with three variables (power, appropriateness, and IRQ).  Of all subjects 
who were included in the ANCOVA model, 98 respondents reported that their hospital had a 
policy that addressed off-label medication use.  The results did not change the pattern of 
significant effects except that, unlike the case of hospital type, power differential and 
appropriateness interaction became marginally significant (p<0.10).  It may be argued that the 
results from this analysis are expected and may appear redundant given that groups were similar 
with respect these variables.  However, because our measures are not free from measurement 
error, the objective was to rule out any potential threat that may be associated with these 
variables.  Do perceptions about key variables differ in different types of institution?  It was 
observed that while hospital type did not affect the way expert power differential, 
appropriateness, or IRQ were perceived, the presence of an off-label medication use policy 
seems to have marginal effects – main effect of policy on power (p=0.097) and interaction of 
102 
 
appropriateness group and policy on appropriateness (p=0.055) – on how appropriateness and 
relative expert power are perceived. 
The impact of inclusion of pharmacists who reported to spend 10% of their time or less 
on clinical duties also was investigated.  The study obtained responses from 51 pharmacists who 
reported to spend currently 10% or more of their weekly working hours on clinical duties.  
Percentage of time spent on clinical duties and its interaction with appropriateness, power 
differential, and IRQ were added to the original ANCOVA model and the analysis was run 
again.  No changes in significant effects were observed in the new model as compared to the 
main model except that time on clinical duties and its interaction with relational impact were 
marginally significant (p<0.1).  Interestingly, while significance of previously found effects were 
retained, the main effect of power differential also became marginally significant (p=0.052) once 
newly added interaction terms were dropped.  However, when people with less than 10% time on 
clinical duties were excluded and the model was run, main effects of appropriateness and IRQ 
and their interaction remained significant (p<0.05) and so did covariates as in the original model.  
The loss of significance of the interaction effect between power and IRQ, which was otherwise 
significant, was further investigated.  As reported before, group composition was not different 
based on time spent on clinical duties.  Similarly, the number of respondent pharmacists reported 
to devote less than 10% and 10% or more of time on clinical service in each experimental group 
were not different (χ2= 0.578, df=3; p=0.90).  ANOVA analyses were performed to examine if 
they had different perception of expert power differential, appropriateness, and relational impact.  
These two groups of pharmacist respondents did not differ in any of the three perceptions 
mentioned above as revealed by insignificant (p<0.05) interactions and the main effects of the 
dichotomous variable -time spent on clinical duty.  Thus, it is possible that the failure to observe 
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significant power-IRQ interaction in pharmacists who devote 10% or more time may have been 
caused by loss of power. 
During the conceptualization phase of this project, concerns were raised that responses by 
pharmacists regarding willingness to influence may be subject to social desirability bias.  It was 
suggested that including a related, but different, construct (i.e., intention to act) might provide a 
validity check of the results.  Items measuring likelihood to act (intention) immediately followed 
the measure of the DV in the survey questionnaire.  Likelihood to act showed high and positive 
correlation (p<0.05) with the DV.  ANCOVA analysis on likelihood to act did not replicate the 
results but showed similar trends.  While the interaction of IRQ with power differential and 
appropriateness remained marginally significant (p<0.10), the main effect of power differential 
was no longer significant (p=0.34).  However, IRQ and appropriateness remained significant 
(p<0.05).  Interestingly, the pattern of observed cell means (Table 15) makes strong sense.  
Although likelihood of intention was a different, but related, construct, such trends of similarities 
in results may increase our confidence in the findings of the study. 
Table 15: Observed Cell Means of Likelihood to Act 
 
Expert power 
differential 
Degree of 
appropriateness 
Mean 
Std. 
Deviation 
N 
GP-low Experiment/low 5.728 1.306 59 
Off-label/high 4.611 1.611 60 
Specialist-high Experiment/low 5.246 1.617 57 
Off-label/high 4.404 1.938 66 
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CHAPTER 5 
INTERPRETATION AND CONCLUSION 
Off-label prescribing has drawn a lot of attention from different interested parties both 
within healthcare and in society.  A substantial extent of effort has been driven into examining 
the prevalence, defined broadly, of off-label prescribing in current medical practice (Cuzzolin, 
Zaccaron, and Fanos, 2003; Radley, Finkelstein, and Stafford, 2006).  Additionally, the known 
literature focuses, to a relatively lesser extent, on explanations as to why such behavior exists in 
the first place.  For example, some studies attempted to understand why physicians prescribe 
medications off-label and elucidate the factors that were associated with such practice (Ekins-
Daukes et al., 2005; Lin, Phan, and Lin, 2006).  Although not appropriate in all cases, much of 
current opinion stands in favor of prescribing medicines off-label; however, judicious use is 
expected.  In other words, using the privilege where it is needed and justified has the potential 
greatly to benefit patients.  Thus, attention should be paid to improve the quality of off-label 
prescribing emphasizing an extended and extensive judgment of appropriateness.  Although 
physicians have been surveyed sporadically to understand off-label medication use, pharmacists 
were neglected largely in the literature.  Thus, the present study was undertaken to explore if 
quality initiatives could be strengthened by pharmacists who are recognized as experts in 
pharmacotherapy.  Specifically, the study focused on whether pharmacists were willing to 
influence the off-label prescribing behaviors of physicians.  Like other studies that examined 
interpersonal relationships in healthcare (Fung, 1991; Raven, 1992), social power, a 
psychological construct, was one of the focal variables in the study.  Perceived expert power 
difference, perceived appropriateness of the off-label prescription, and perceived negative impact 
on relationship quality between the pharmacist and the prescriber following an attempt to 
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influence were independent variables that examined pharmacist willingness to influence off-label 
prescribing.  Using an experimental design, this survey examined the following propositions: 
P1: The pharmacist’s perceived relative expert power in relation to the physician is 
positively associated with the pharmacist’s willingness to influence off-label 
prescribing. 
P2: The perceived appropriateness of prescription medication is negatively 
associated with the pharmacist’s willingness to influence off-label prescribing. 
P3: The effect of the pharmacist’s relative expert power on the pharmacist’s 
willingness to influence off-label prescribing is moderated by the perceived 
appropriateness of prescription medication. 
P4 The effect of the pharmacist’s perceived relative expert power on willingness 
to influence off-label prescribing is moderated by the perceived impact on 
relationship quality with the physician as perceived by the pharmacist. 
 
Perceived Relative Expert Power 
In the present study, vignettes were used to manipulate the perceived expert power 
differential between the prescribing physician and the pharmacist respondent.  Pharmacists 
assigned to the specialist group rated the physician as having more expert power (high power 
differential) than did those pharmacists assigned to the generalist group.  As a result, the 
manipulation of power was determined to be effective.  The results from the present study are 
summarized in Table 16 and showed that pharmacist’s perceived relative expert power in 
relation to physician was associated with pharmacist’s willingness to influence off-label 
prescribing.  However, contrary to what was expected, willingness to influence was higher when 
power differential increases (Table 14).  This finding is unexpected; however, it may be 
explained possibly by uncertainty reduction theory (Berger and Calabrese, 1975).  Uncertainty 
reduction theory proposes that increases in information seeking behavior may be observed to 
reduce uncertainty.  The study limited the pharmacist’s evaluation of the physician’s superiority 
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in knowledge to the descriptions in the vignettes.  Such uncertainty may be reflected in the 
evaluation of specialists as revealed by the mean rating of power differential of specialist group 
that stands very close to 4 or midpoint, which means not sure or no opinion, of the scale (Table 
8).  As a result, uncertainty in the pharmacist’s mind may have expressed itself as willingness to 
influence when it may have actually been an action to seek clarification about the rationale 
regarding the prescription.  In the light of this finding, several points should be mentioned.  First, 
the effect size of power differential may be small as opposed to medium (assumed during sample 
size calculation prior to the execution of the study).  This point may be substantiated by the fact 
that, although statistically different, the difference in expert power differential as perceived by 
pharmacists in the two groups was, practically speaking, very narrow.  In general, pharmacists 
slightly disagreed that the physician described in the scenario had more expert power than 
pharmacists as indicated by the mean scores that lay between 3 and 4 on a 7-point scale (Table 
8).  If the true effect size is small, increasing sample size may reveal this effect, if it exists, more 
strongly.  Secondly, the independent effect of power differential may not either exist such that it 
influences pharmacist’s decisions about professional judgment or it may not have any practically 
meaningful effect.  Within the context of pharmacist-physician communication, past research 
found that power differential was not a significant predictor of pharmacist’s communication 
behavior (Lambert, 1996).  Presently, pharmacy education in the US emphasizes heavily 
pharmacotherapeutics through its didactic curriculum and clinical clerkships (ACPE, 2006).  
Thus, pharmacists educated in this manner may not perceive physicians superior concerning 
expertise in medication-related matters.  Moreover, information about the residency training of 
the respondents was not collected during the project.  It is possible that professional socialization 
occurred differently for pharmacists who completed residencies and may have affected the 
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manner in which pharmacists perceived their interaction with physicians.  Lastly, the responses 
may suffer from social desirability bias that may be operating in different directions in different 
experimental groups related to power.  This possibility is supported by the pattern of mean 
responses, as explained below, on the power manipulation.  In general, pharmacists may perceive 
physicians slightly superior in expert power but not so much that the gap in perceived power 
differential is large depending on physician specialty.  In other words, in the generalist group 
there may be floor effect such that physicians have to be rated more powerful, whereas in the 
specialist group there may be both floor and ceiling effect.  This effect may be accentuated by 
the characteristic, i.e., high clinical acumen, of the respondents.  Moreover, the standard error of 
the mean scores in the power manipulation (Table 8) was larger in the specialist group even 
though the number of subjects was greater.  A relatively less precise estimate in the specialist 
group may attest to the existence of such an effect.  As such, the potential bias may have affected 
responses to the DV.  For example, within the high appropriate group, willingness to influence 
was second highest among all – conceptually predicted to be the lowest – in the specialist group 
as compared to the generalist group (Table 14).  Although some potential explanations are 
offered below, this pattern of response remains to be understood clearly.  Finally, power 
differential may not have any independent effect but may act in a complex manner as reflected 
by the interaction of perceived power differential with IRQ.  At this point, it can be noted that the 
independent effect of power did not appear in some of the post hoc analyses (Table 16).  Thus. 
the main effect of power differential should not be emphasized or, at best, it should be 
interpreted cautiously.  
112 
 
Table 16: Summary of Results 
Analysis Model Results 
Main Analysis 
Full ANCOVA model 
Power, Appropriateness, IRQ, 
Power*Appropriateness^, 
Power*IRQ, 
Appropriateness*IRQ 
ANCOVA within Specialist  Appropriateness, IRQ, Appropriateness*IRQ 
ANCOVA within Generalist1 Appropriateness^ 
ANCOVA within high 
Appropriateness  
ANCOVA within low 
Appropriateness Power, Power*IRQ 
   
Post-hoc analysis 
ANCOVA: AMC vs. Non-
AMC included 
Power, Appropriateness, IRQ, 
Power*IRQ, 
Appropriateness*IRQ; 
ANCOVA: with Policy vs. 
No-policy2 included 
Power, Appropriateness, IRQ, 
Power*Appropriateness^, 
Power*IRQ, 
Appropriateness*IRQ 
ANCOVA: Clinical service 
(<10% vs. ≥10%) included 
Power, Appropriateness, IRQ, 
Power*Appropriateness^, 
Power*IRQ, 
Appropriateness*IRQ 
Duty^, Duty*IRQ^ 
ANCOVA excluding 
pharmacists with Clinical 
service <10%  
Appropriateness, IRQ, 
Appropriateness*IRQ 
ANCOVA: Likelihood to act 
as dependent variable 
Appropriateness, IRQ, 
Appropriateness*IRQ^, 
Power*Appropriateness^ 
Terms that appear are significant at p<0.05 level. 
^ p<0.10 
1 p >0.05 for all variables of interest;  
2 Two-way ANOVA analyses showed policy had marginal (p=0.097) effect on power perception 
and the interaction of appropriateness and policy on appropriateness perception (p=0.055). 
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Perceived Appropriateness of Off-label Medication 
The appropriateness of off-label prescribing, not the practice itself, is debated most 
heavily and has raised concerns among different stakeholders (AHRQ, 2007).  Knowing this, the 
judgment of appropriateness is critical and as long as appropriateness is evaluated carefully, off-
label prescribing has the potential to provide positive outcomes not achievable with current 
therapies.  Although “appropriateness” may be debated, or driven by case-specific variables, this 
study relied on ratings on different aspects of appropriateness as recommended by a standard 
drug monograph.  During the instrument development and pretest, general opinions about the 
appropriateness of the medication demonstrated that the two examples of off-label prescriptions 
were, in fact, different on this variable.  The manipulation check further confirmed that the two 
medications were indeed considered different, as hypothesized, in terms of appropriateness.  
Unlike the power manipulation, the difference in appropriateness as perceived by pharmacists in 
the respective groups was large and ratings lay on two sides of the mid-point of the scale (Table 
8).  The between-subject ANCOVA results confirm that perceived appropriateness of medication 
is negatively associated with pharmacist’s willingness to influence off-label prescribing.  In other 
words, if a pharmacist has evidence that does not support an off-label use he or she will be more 
willing to influence the prescriber’s judgment.  This result makes sense and is consistent with the 
pharmacy literature.  Past studies confirm that pharmacists intervene in order to improve 
prescribing and to change prescribing practices that are considered inappropriate (Rupp, 
DeYoung, Schondelmeyer, 1992; Hanlon et al., 1996).  Moreover, institutional practices in many 
US hospitals are governed by protocols or policies; practices that deviate from this norm may 
make the pharmacist less concerned about questioning the judgment of physician.  In the present 
study, pharmacists in both appropriateness groups demonstrated a willingness to influence; 
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however, those in the low appropriateness group reported a higher willingness to influence the 
prescriber.  A potential explanation for pharmacist’s higher willingness to intervene in the case 
of evidence-based off-label medicine may be because they may opine that any medication order 
that is not on-label necessitates additional judgment.  The present study does not permit us to 
draw such a conclusion; however; performing a role that brings about expert evaluation by 
pharmacists would, at the very least, assure society about safe and effective prescribing and 
medication use.  Another potential reason may be the effects of other variables and their 
interactions (three-way type of influence).  In this context, it should be mentioned that the main 
effect of a variable cannot summarize its effect in the presence complex interactions.  Thus, it is 
emphasized here that the main effect of appropriateness is not sufficient and not appropriate to 
understand its effect on willingness to influence as revealed in the study. 
Table 17: Estimated Marginal Means of Power-Appropriateness Interaction (N=242) 
Dependent Variable: willingness to influence 
Degree of 
appropriateness 
Expert power 
differential 
N Mean 
Std. 
Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Experiment/low 
GP-low 59 5.696 0.140 5.420 5.973 
Specialist-high 57 5.453 0.140 5.177 5.729 
Off-label/high 
GP-low 60 5.399 0.138 5.127 5.672 
Specialist-high 66 5.673 0.131 5.414 5.932 
 
Although the study’s third proposition (the effect of pharmacist’s relative expert power 
on pharmacist’s willingness to influence off-label prescribing is moderated by perceived 
appropriateness) was not supported, the interaction between appropriateness and IRQ, was 
significant.  Proposition 3 was not supported possibly because of some of the limitations or 
reasons discussed in the previous discussion on social power.  Specifically noteworthy is that the 
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study may lack power to detect such effect.  It can also be noted here that the plot (Figure 3) of 
the interaction between power and appropriateness, although not significant (p=0.063), presents 
an interesting reverse direction effect.  Although it cannot be concluded, it is possible that low 
appropriate conditions create an uncertainty, as may be implied by higher standard error in the 
low appropriate condition (Table 17).  When a highly expert consultant physician writes an off-
label prescription that appears to be lacking in evidence for its use, because of uncertainty, the 
evaluating pharmacist might attribute the lack of evidence to either lack of information possessed 
by the pharmacist or to the physician’s special expertise and skill that are critical to utilizing such 
information.  Under such uncertainty, pharmacists may rely on a limited number of heuristics 
(Kahneman and Tversky, 1973) such as specialty and experience of the physician and as a result 
overestimate the physician’s power such that it reduces their relative ability to perceive risk. 
Now one may argue that it should not happen as information power was not significant.  
However, rather than experimentally controlling for information power, it was measured.  In 
addition, information may be meaningful but meaning is not inherent in information; it requires 
interpretation (Johnson, 1993).  Due to lack of interpretation of information or uncertainty, the 
pharmacist may perceive the physician to be more expert than the physician actually is and thus 
reduce his or her willingness to influence.  Alternatively, fibromyalgia, a disease state that is 
debated (Berenson, 2008), might have prompted pharmacists’ willingness to report that they 
would intervene when the objective of the interaction was to secure knowledge from the 
specialist.  
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Impact on Relationship Quality (IRQ) 
In the framework of the power/interaction model of interpersonal influence, Raven 
(1992) postulated that influence attempts might result in negative outcomes in interpersonal 
relationships.  The social psychology literature is replete with studies that show such outcomes 
(Yukl and Tracey, 1992) exist.  In the context of the pharmacist-physician relationship, concerns 
such as those mentioned are not unfounded.  As a result, effort was made to measure the 
pharmacist-physician collaborative relationship (Zillich et al., 2004; Doucette, Nevins, 
McDonough, 2005).  Unlike the other two independent variables, IRQ was measured with 
multiple items that were taken from multiple studies (Morgan and Hunt, 1994; Roberts, Varki, 
and Brodie, 2003; Dobson et al., 2006) such that it examined all relevant negative outcomes.  
However, in contrast to the conceptualization, IRQ emerged as a two-factor construct.  It should 
be mentioned that the relationship quality scale proposed by Dobson et al., (2006) also had two 
factors (relationship with physician and profession prepared to participate).  However, in order to 
be consistent with the study’s conceptualization and in the interest of model parsimony a single 
factor IRQ that explained a substantial part of total variance was used in subsequent analysis.  
Pharmacists, in general, did not perceive a substantial negative impact on their interpersonal 
relationship with the prescriber in the event that they made an attempt to influence (mean=2.36, 
s.d.=1.24 using a 7-point scale (1=not at all, 7=absolutely)).  IRQ was measured after 
manipulations were introduced.  However, manipulated variables did not appear to affect (p>0.1) 
the manner in which pharmacists responded to the IRQ measure. 
After controlling for covariates, perceived expert power differential between the 
physician and pharmacist affects pharmacist’s willingness to influence differentially in different 
power groups with changes in IRQ as perceived by the evaluating pharmacist (Figure 1).  Thus, 
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in situations where the pharmacist perceives a high power difference, the pharmacist’s 
willingness to influence off-label prescribing reduces more sharply with an increase in perceived 
IRQ as compared to willingness to influence in the low power difference condition.  In other 
words, when there is an increase in pharmacist’s relative power (as in the generalist group) IRQ 
has a weaker effect on the pharmacist’s willingness to influence off-label prescribing.  This 
statement is further supported by the findings in the post-hoc analyses.  In the generalist group, 
only appropriateness significantly affected the pharmacist’s willingness to influence (Table 16).  
This is an interesting finding and is consistent with what Raven (1992) suggested.  It can be 
noted here, that power is not a zero sum game and in order to be effective, professional groups 
may exercise power over decisions within their sphere of competence (Flood and Scott, 1978).  
Although perceived power differential has been conceptualized as a physician’s power it can be 
applied to a pharmacist’s power thus making the role of power differential more generalizable. 
While the study did not hypothesize a priori the interaction between appropriateness and 
IRQ, post-hoc analysis supported the moderating effect of IRQ being more pronounced in the 
low appropriateness group than in the high appropriateness group (Figure 2).  When pharmacists 
are less concerned about relational outcomes, decreases in appropriateness of therapy appear to 
increase the pharmacist’s willingness to influence.  What this implies is that appropriateness (or 
lack thereof) of a prescription creates a logical ground for the pharmacist to make an influence 
attempt on a physician; however, it may not be very straightforward if pharmacists are concerned 
about the outcomes of those influence attempts. 
Indeed, like any other professional relationship, IRQ seems to have a consistent and 
pronounced influence in pharmacists’ decision-making.  This is consistent with the pharmacy 
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literature where concerns about fostering good relationships with physicians are echoed (Comer 
et al., 2009). 
The results of the study appear to be robust.  Under different assumptions as examined in 
several post-hoc analyses, the effect of variables of primary interest did not change.  A striking 
difference in the results was observed when the post-hoc analysis included pharmacists spending 
10% or more of their working hours on clinical pharmacy services or direct patient care services.  
Even in this condition, the same effects as in the original model were observed with the 
exception of those related to power differential.  One reason for such a result may be a lack of 
power.  Expert power appears to have a subtle effect.  As a result, when clinical duty is added as 
continuous variable in the model some effects involving expert power reappeared.  Another 
reason for such result may be that the effect of expert power is subsumed in responsibility and 
power of dependence both of which appear significant consistently as these are groups that may 
perceive such duties as part of their normal routine.  For some, it may be disturbing that the 
concern over the impact on relationships overrides or dictates over evidence-based 
appropriateness judgments with regard to pharmacist’s willingness to influence.  However, such 
findings represent realism.  More assuring was the pharmacists’ willingness to influence off-
label prescribing, in general.  Although concerns about relational consequences and attempt to 
influence relationship exists, increasing pharmacist’s expert power or another social power (i.e., 
decreasing power differential) may alleviate some of this concern.  Although this study did not 
provide evidence to conclude as such, it is also possible that in the present practice framework, 
pharmacists are not interacting with physicians on this issue on a regular basis.  Thus, concerns 
about relationships may be overstated.  
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LIMITATIONS OF THE STUDY 
This study has limitations that may affect generalizability and should be kept in mind 
while interpreting its results.  Important limitations and a discussion of their potential impact on 
the findings of the present study follow. 
Manipulation of variables 
One of the assumptions of ANCOVA is that independent variables (IV) do not affect 
each other.  Manipulation checks reveal that power differential may have affected the 
appropriateness ratings by the respondents.  This means that the medications appeared more 
appropriate if it was prescribed by a specialist rather than a generalist (Table 18).  In the real 
world, expert power and appropriateness judgments are combined inextricably and thus there 
was a degree of realism in this study.  Order bias may be present in the study because the power 
manipulation check was introduced before the appropriateness manipulation check in all 
instances, thus creating an anchoring effect (Landon, 1971) and as such, this effect appeared only 
in the manipulation rating.  Although manipulation checks that are rated much later do not 
convincingly state that IVs affect each other that were fixed by the design in the present study, 
the results should be cautiously interpreted.  Under the circumstance of non-independent or 
falsified manipulation, misleading results may be possible (Perdue and Summers, 1986).  
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Table 18: Tests of Between-Subjects Effects on Independence of Independent Variables 
Dependent Variable: appropriateness 
Source 
Type III Sum of 
Squares 
df Mean Square F Sig. 
Corrected Model 216.52a 3 72.17 53.57 <0.001 
Intercept 5073.42 1 5073.42 3765.47 <0.001 
Power dif 19.81 1 19.81 14.71 <0.001 
Appropriateness 193.91 1 193.91 143.92 <0.001 
Power dif * Appropriateness 0.01 1 0.014 0.01 0.919 
Error 346.27 257 1.35   
Total 5674.00 261    
Corrected Total 562.79 260    
a. R Squared = 0.385 (Adjusted R Squared = 0.378) 
 
Vignette design 
The study designed four vignettes that came from crossing two manipulated variables.  
Vignettes have been used in past research in clinical settings including studies examining quality 
of clinical practice (Epstein et al., 2001; Peabody et al., 2004).  However, the vignettes had some 
limitations in terms of providing adequate information (e.g., treatment history) that may be 
required for evaluation by pharmacists.  In other words, the vignette might lack realism and may 
suffer because of lack of essential information.  It is also possible that vignette had a cuing effect 
for the appropriateness measure and demand characteristics for the DV.  Responses to vignettes 
with cueing items are believed to lead to overestimation of performance (Sandvik, 1995) and 
may have inflated the pharmacists’ willingness to influence off-label prescribing.  How a 
pharmacist assesses appropriateness in a real-life off-label prescribing situation may not be 
reflected accurately using a vignette-based research design.  
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Coverage error 
The study sample was not drawn randomly using any probability sampling technique.  
Data collection for this study occurred online through an email invitation sent out by the 
participating state affiliates of the ASHP.  As such, some pharmacists may not hold membership 
with the respective state affiliate.  Additionally, it is possible that pharmacist members may not 
have email access. 
Response rate and related issues 
Generally, it is considered good practice, if not mandatory, in survey research to report 
response rate, which provides primary evidence about generalizability of the results.  In addition, 
nonresponse bias may be examined by using different methods for the purpose of 
generalizability (Singleton and Straits, 2005).  This study adopted a facilitated distribution 
approach via email.  As a result, it was not possible to estimate the number of pharmacists who 
received the request to participate in the study and to determine when they received it; it was not 
possible to calculate response rate and evaluate potential nonresponse bias, as is suggested 
(Armstrong and Overton, 1977).  Attrition rate during this study was high.  Many of potential 
respondents (approximately 40%) left very early after starting the survey.  This group of people 
may have different opinions on the issue than those responded.  The design of the present study 
does not allow us to analyze this group of potential participants because the respondent 
terminated the survey before they were exposed to the experimental treatment.  Thus, it can be 
argued that attrition rate did not occur because of treatment, a noted threat to internal validity.  
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Issues related to measures 
In this study, measures were adapted from past studies that were not always related to 
health care.  Although the measures used were all multi-item measures and the reliability 
estimates of the scales were good or acceptable, caution should be exercised while interpreting 
the results for several reasons.  First, these scales are not well validated within the context of 
health care.  Second, some measures did not behave according to conceptualization.  For 
example, factor loadings of items of referent power were ambiguous and the scale’s reliability 
was poor.  Referent power may produce a halo effect or sleeper effect (French and Raven, 1965) 
and is related to expert power.  The effects of referent power could not be adjusted, which may 
or may not bias the result.  The information power scale emerged as a two factor solution as 
opposed to theory that suggested that it was unidimensional.  The IRQ measure also exhibited 
this characteristic.  As a result, the information power scale that was used in the analysis may not 
adequately capture what it purported to do.  While conducting post-hoc analysis using the 
likelihood to act scale it was observed that information power became significant.  It was not 
clear if that result occurred because of measurement inadequacy.  One of the assumptions of 
ANCOVA is that covariates are measured without error.  This assumption may not be tenable, 
especially in the light of the fact that our measures may have issues as described previously.  
Although expert power or appropriateness was not used in the analysis such concerns may apply 
to the measures that were included in the analyses as well.  Measurement errors may have 
serious consequences on the conclusions of survey studies (Hair et al., 2006).  Although the post 
hoc analyses provided some confidence, estimates may not be very robust unless advanced 
techniques such as structural equation modeling are used to account for measurement errors.  
Finally, the disease state fibromyalgia might have driven the response patterns.  For example, the 
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existence of fibromyalgia is debated (Berenson, 2008) and if respondents believed it as such it 
might have affected their response. 
Future Research Opportunities 
The dependent variable in the present study was willingness to influence.  Responses to 
willingness to influence, on average, were on the higher side of the scale (all cell means above 
5.5) and cell means were very close.  It could be such that pharmacists are by nature willing to 
influence regardless of whether the prescription is off-label or on-label.  Alternatively, the word 
“off-label” may have sensitized respondents and thus created demand characteristics.  Future 
research should explore pharmacist’s willingness to influence off-label prescribing in 
comparison to on-label prescribing.  Another potential reason for such high scores may stem 
from social desirability bias.  Although suggested techniques (e.g., assurance of anonymity, 
highlighting the importance of the topic in cover letter, etc.) (Singleton and Straits, 2005) had 
been applied to control such bias, it may be still an issue.  Specifically, impression management, 
which is associated with the desire to present oneself in a socially desirable manner (Paulhus, 
1991) may be driving the response patterns observed.  Respondents may be motivated to bias 
their self-reported responses to the extent that the value is strongly prescribed or expected within 
the social context or norms and has social meaning (King and Bruner, 2000).  Future research 
should disentangle the effect of such bias, if any. 
Although pharmacists may be willing to influence, do they actually influence – moot 
point of substantive concerns – when confronted with off-label prescribing situations that require 
additional evaluation?  In this study, the cell means of likelihood of influence were lesser then 
their respective average values for willingness to influence.  The models examining willingness 
to influence and likelihood to act showed little difference with the most striking being the 
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significance of information power in the latter, although differentiation between these constructs 
exist (Armitage and Conner, 2001).  The intention-behavior literature suggests that intention 
does not correspond to behavior always (Sniehotta, Scholz, and Schwarzer, 2005; Sheeran, 
2002).  Another interesting question that can and should be explored is what mode of 
communication strategies pharmacists adopt when making their influence attempts.  Pharmacist-
physician communication is understudied relatively when compared to patient-physician or 
patient-pharmacist communication.  Thus, it would be interesting and enlightening to examine 
pharmacist-physician communication with regard to influencing off-label prescribing, especially 
in those low appropriate conditions where a degree of uncertainty exists. 
It should be noted here that in all of the aforementioned analyses, appropriateness was a 
fixed effect variable; however, it can also be considered a random effect variable with the 
assumption that two scale points as represented by two groups were randomly chosen on a 
continuum of appropriateness scale.  Alternatively stated, can the study results be replicated in 
situations that compose the universe of degrees of appropriateness? 
The manipulation check on the power measure raises an interesting point.  The large 
standard error seen in the specialist group reflects variability of the scores and attests to 
imprecision of the estimate and implies that our tests may have little power (Meyer and Well, 
2003).  In fact, this study was not powered to detect all effects in the model, including power and 
appropriateness interaction.  Future studies should be appropriately powered to examine the 
effect before such effect is ruled out with confidence.  This is important especially due to the 
contaminating effect of manipulation. 
Finally, the selected disease condition in the vignette did not have imminent life 
threatening potential.  The existing literature on off-label prescribing is replete with evidence that 
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off-label prescribing occurs largely in life threatening diseases (Brosgart et al., 1996; Poole and 
Dooley, 2004).  Pharmacists’ intent and perceived responsibility in those cases may be 
interesting to study.  It may be worth studying especially, in the light of the fact that 
responsibility was a strong and consistent predictor of willingness to influence.  In addition, 
future research may also revisit the results of the study in other disease conditions. 
CONCLUSION 
This study examined pharmacist’s willingness to influence off-label prescribing.  
Willingness to influence represents a pharmacist’s willingness to ensure the rationality of off-
label prescribing.  Experimental manipulations were used to examine the effect of perceived 
relative expert power and perceived appropriateness on willingness to influence.  Perceived 
negative impact on interprofessional relationship quality was measured to investigate its 
moderating effect on a pharmacist’s willingness to influence.  The effects of power of 
dependence, informational power, communication effectiveness, attitude, and responsibility were 
statistically controlled.  The variables were measured using multi-item measures that showed 
acceptable or satisfactory reliabilities.  Physician’s expert power relative to pharmacist or 
perceived power differential between the pharmacist and physician affects pharmacist’s 
willingness to influence off-label prescribing.  Perceived appropriateness of off-label 
prescription medication negatively affects pharmacist willingness to influence as one would 
expect.  However, the effect of perceived power differential on willingness to influence does not 
appear to depend on perceived appropriateness.  In addition, significant moderating influences of 
perceived impact on relationship quality were observed.  With an increasing perception of impact 
on relationship quality, perceived expert power differential more negatively affects pharmacist’s 
willingness to influence.  Thus, it indicates pharmacists are less willing to influence when 
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perceived power differential increases (e.g., specialist physician vs. general physician) if such an 
attempt is speculated to bring about higher negative impact on the interprofessional relationship.  
Similarly, combined effect of appropriateness and impact on relationship quality was observed.  
With anticipation of increasing adverse relational outcomes, pharmacist’s willingness to 
influence off-label prescribing decreases more in the low appropriate condition than in the high 
appropriate condition.  That is, pharmacists are less willing to influence off-label prescribing that 
is perceived low as compared to high in appropriateness under an anticipated condition of 
adverse relational consequences.  Reverse phenomenon occurs when low negative outcomes 
anticipated.  Interestingly, perceived negative impact on relationship quality has an independent 
effect on pharmacist’s willingness to influence.  This study has basic requirements (random 
assignment, manipulation of IV, measurement of DV) of a true experiment that ensure the 
internal validity of the results (Singleton and Straits, 2005). In addition, the study had 
participants from across the US including pharmacists from a mix of large and small states, 
academic and nonacademic hospitals, private and public hospitals and pharmacists having 
different job titles or responsibilities.  Thus, such heterogeneity of respondents also ensures 
generalizability of the results of the study.  In summary, the findings show that pharmacists are 
willing to ensure rationale behind off-label prescribing by intervening in off-label prescribing 
situations.  This should comfort the patient community and justify the pharmacist’s role and 
strengthen their image as a provider of evidence-based healthcare solutions. 
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APPENDIX A 
Experimental Vignette 
 
 
 
Dr. Smith is a general practitioner [rheumatologist] and joined your hospital two years ago. 
[Dr. Smith is a highly recognized expert in the field of rheumatology. Dr. Smith is 
considered an extremely knowledgeable physician with extensive clinical experience in 
rheumatology.] Dr. Smith has 5 [20] years of experience of clinical practice. Previously, Dr. 
Smith has [successfully] treated a few [many] patients with various medications prescribed 
for off-label indications. 
 
Dr. Smith has written an order for fluoxetine for the treatment of diabetic neuropathy 
[fibromyalgia] for Jody Jones, 35, who was admitted to your hospital 1 day ago for a minor 
injury. Fluoxetine treatment has been ordered using 20 milligrams/day for seven days and 
then will be titrated until 40 milligrams/day is reached in two weeks in an out-patient 
setting. 
 
Existing [peer-reviewed] reports on efficacy of fluoxetine in diabetic neuropathy 
[fibromyalgia] are inconsistent and inconclusive [favorable]. This information is based on 
data derived from disjointed personal experience, or a few case reports [well-designed 
randomized controlled trials or well-designed nonrandomized studies (e.g., cohort studies, 
case-control studies, observational studies)]. 
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APPENDIX B 
Study Instruments 
  
Block Filter
Pharmacist in off-label prescribing - final
Q1.0
  Thank you for agreeing to help a graduate student with this Master's thesis project.
Please complete this short survey as INCOMPLETE/ partial responses may NOT be analyzable.
Q1.1
Yes No
Are you a pharmacist practicing in any type of hospitals?
If Yes Is Selected, Then Skip To End of Block
Q1.2
Yes No
Researchers at the Department of Pharmacy Administration of the University of Mississippi School of Pharmacy strive to address issues
facing pharmacists, the business and profession of pharmacy, and patient care.  In order to access pharmacists and pharmacy technicians for
future research, the Department intends to develop a research panel.  Such panel will be used for ACADEMIC RESEARCH ONLY.  It is
assured that your email id and your practice information that you provide, if any, will be under the safe custody of the Department and
managed following professional and ethical norms. 
Do you wish to be considered for inclusion in the research panel being developed by the Department?
If No Is Selected, Then Skip To End of Survey
Display This Question:
If  Researchers at the Department of Pharmacy Administration ... Yes  Is Selected
Q1.3 Please provide your e-mail id(s) for participating in the research panel.
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Display This Question:
If  Researchers at the Department of Pharmacy Administration ... Yes  Is Selected
Q1.4 Please provide the following information.
 
Job title
State where you practice
Practice setting
Q1.5  
If   Is Displayed, Then Skip To End of Survey
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Block 11
Pharmacist in off-label prescribing - final
Q2.1 INSTRUCTIONS
Please carefully read the instructions before you answer and be assured that there are NO right or wrong answers. Without your honest and thoughtful
response, the objectives of this research will NOT be realized.
Definitions: 
 
OFF-LABEL PRESCRIBING is the act of prescribing a medication outside its FDA-approved (labeled) recommendations, including different disease
conditions, different dosage (over or under) range, different age groups, different route of administration, and different formulations.
 
In this survey, we are also interested in INDICATION-BASED off-label prescribing. This occurs when a medication is prescribed outside its
FDA-recommended (labeled) disease conditions (e.g., β-blockers prescribed for the treatment of thyrotoxicosis or neurotic disorders, which are not
approved indications for β-blockers).
This survey is organized into three sections:
Section I: Questions regarding your beliefs and the roles of your physician colleagues
Section II: Clinical scenario presentation and reaction (IMPORTANT)
Section III: Demographic information
Q2.2 Section I
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Q2.3 We would like you to think about the hospital in which you practice currently. Considering the physicians who practice in your hospital,
please indicate your level of agreement or disagreement with each of the following statements using a 7-point scale where 1=strongly
disagree and 7=strongly agree.
Strongly
disagree =
1 2 3 4 5 6
Strongly
agree = 7
Unless I help physicians select medications, their
job will be more difficult.
I understand that physicians really need my help
with the selection of medications.
I realize that physicians need assistance and
cooperation from those working with them.
It is clear to me that physicians really depend on
me to help select medication.
Because I respect physicians, I do not wish to
disagree with them.
I see physicians as persons with whom I can
identify.
As part of the health care team, physicians and I
should see eye-to-eye on things.
I look up to physicians to model my work.
Physicians have better rationale for selecting
medications than I do.
I have better information required for the selection
of medications than physicians possess.
I have more control over information required for
selecting medications than physicians do.
I have more access to information required for the
selection of medications than physicians do.
Physicians have more explanations for the basis
of medication selection than I do.
Q2.4 The following statements address your interactions with your physician colleagues. Please rate your behavior using a 7-point scale where
1=never and 7=always.
Never =1 2 3 4 5 6 Always = 7
I have trouble convincing physicians to do what I want them to
do.
I can persuade physicians to my position.
I accomplish my communication goals.
Q2.5 As mention before, off-label prescribing is prescribing a medication outside its FDA-approved (labeled) recommendations. Considering your
roles in off-label prescribing, please indicate your level of agreement or disagreement with the following statements on a 7-point scale where
1=strongly disagree and 7=strongly agree.
Strongly
disagree =
1 2 3 4 5 6
Strongly
agree = 7
I have to evaluate off-label prescriptions in order for my
performance to be considered satisfactory.
Evaluating off-label prescriptions is my responsibility.
I consider evaluating off-label prescriptions as my obligation or
duty.
I would blame myself if I do not evaluate off-label prescriptions
satisfactorily.
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Q2.6 Note that INDICATION-BASED off-label prescribing is prescribing a medication outside its FDA-recommended (labeled) disease conditions.
Please respond to the following statements using a scale of 1 (strongly disagree) to 7 (strongly agree).
Strongly
disagree =
1 2 3 4 5 6
Strongly
agree = 7
Indication-based off-label prescribing is important for assuring
appropriate treatment.
Indication-based off-label prescribing is advantageous for
patients.
Indication-based off-label prescribing provides effective
therapies to patients.
Indication-based off-label prescribing ensures safety.
Q2.7 Section II
Q2.8  
IMPORTANT:
 
Please read the hypothetical situation very carefully. Imagine yourself as a pharmacist in the following situation.
 
Dr. Smith is a rheumatologist and joined your hospital two years ago. Dr. Smith is a highly
recognized expert in the field of rheumatology. Dr. Smith is considered an extremely
knowledgeable physician with extensive clinical experience in rheumatology. Dr. Smith has 20
years of experience of clinical practice. Previously, Dr. Smith has successfully treated
many patients with various medications prescribed for off-label indications.
 
Dr. Smith has written an order for fluoxetine for the treatment of fibromyalgia for Jody Jones, 35,
who was admitted to your hospital 1 day ago for a minor injury. Fluoxetine treatment has been
ordered using 20 milligrams/day for seven days and then will be titrated until 40 milligrams/day
is reached in two weeks in an out-patient setting.
 
Existing peer-reviewed reports on efficacy of fluoxetine in fibromyalgia are favorable. This
information is based on data derived from well-designed randomized controlled trials or
well-designed nonrandomized studies (e.g., cohort studies, case-control studies, observational
studies).
Q2.9 On the basis of the situation that was just described, please indicate your willingness to act in each of the following ways using a 7-point scale
where 1=not at all willing and 7=absolutely willing.
I am willing to ...
Not at all
willing = 1 2 3 4 5 6
Absolutely
willing = 7
use logic to convince Dr. Smith about the use of the medication
explain the reasons for my request as to why the medication is
appropriate or inappropriate
present Dr. Smith with the information in support of my point of
view about the use of the medication
present a detailed plan that justifies my idea about the use of
the medication
ensure rationale of this medication order with Dr. Smith
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Q2.10 Please indicate your likelihood of acting as described by the following statements where 1=not at all likely and 7=very likely.
Not at all
likely = 1 2 3 4 5 6
Very likely
= 7
I will intervene with Dr. Smith on the medication order.
I will work with Dr. Smith on the medication order.
I will contact Dr. Smith about the medication order.
Q2.11 On the basis of the situation that was described, please indicate how acting on the prescription order may affect your relationship with the
prescriber.  Please indicate your response on a 7-point scale where 1=not at all and 7=absolutely.
 
Contacting Dr. Smith about this
off-label prescription will ...
Not at all =
1 2 3 4 5 6
Absolutely
= 7
diminish Dr. Smith’s willingness to work closely with me
diminish the likelihood that Dr. Smith will continue with my
service
diminish Dr. Smith’s trust in me
diminish Dr. Smith’s counting on my service
diminish the likelihood that Dr. Smith will seek my advice
diminish the extent of patient information sharing between
us
reduce communication between us
make Dr. Smith angry with me
make Dr. Smith annoyed
make Dr. Smith content with my service
make Dr. Smith happy with my service
Q2.12 On the basis of the information in the scenario, please indicate your level of agreement or disagreement with each of the following
statements using a 7-point scale where 1=strongly disagree and 7=strongly agree.
Strongly
disagree
=1 2 3 4 5 6
Strongly
agree = 7
Dr. Smith knows a better way of selecting a drug therapy
than I do.
Dr. Smith knows more about selecting a medication than I do.
Dr. Smith has more clinical knowledge about medicine than I
do.
Dr. Smith has more clinical knowledge about the treatment
than I do.
Q2.13 Based on the information in the scenario, please evaluate the level of appropriateness or inappropriateness of the medication order using a
7-point scale where 1=not at all appropriate and 7=very appropriate.
Not at all
appropriate
= 1 2 3 4 5 6
Very
appropriate
= 7
In my opinion, the medication order is
Overall, the fluoxetine order for fibromyalgia is
149
Q2.14 Section III
 
This section asks about you and your practice setting.
Q2.15
Male Female
Gender:
Q2.16 What was your age on your last birthday?
Years
Age
Q2.17
B.S. (Pharmacy) Pharm.D.
Which of the following describes your pharmacy education? (check all that apply)
Q2.18
Yes No
Do you currently have any BPS specialization?
Display This Question:
If  Do you currently have any BPS specialization? Yes  Is Selected
Q2.19
Nuclear Pharmacy Nutrition Support Pharmacy Oncology Pharmacy Pharmacotherapy Psychiatric Pharmacy
IF YES: Which of the following do you hold? (check all that apply)
Q2.20  For how long have you been practicing ?
Years
In a hospital setting
In this hospital
Q2.21 What percentage of your working hours, on average, do you spend in each of the following activities? (Please be sure the rows sum to 100%)
%
Distributive pharmacy services
Direct patient care/clinical pharmacy services
Administrative duties
Other
Total
Q2.22
Clinical pharmacist Staff pharmacist Pharmacy manager Consultant pharmacist Pharmacy Director
Other (specify)
What title best describes your job? (check all that apply)
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Q2.23
Yes No
Is your hospital an academic medical center? 
Q2.24 The ownership status of your hospital is . . .  (check only one)
a private community hospital (not-for-profit) a federal hospital
a private community hospital (for-profit) a university hospital
a public community hospital other (specify)
Q2.25 In what state is your hospital located?
Q2.26
Yes No
Does your hospital have an Institutional Review Board (IRB)?
Q2.27
Yes No
Does your hospital have any policy regarding off-label prescribing?
Display This Question:
If  Does your hospital have any policy regarding off-label pr... Yes  Is Selected
Q2.28 IF YES, please describe briefly this policy.
Q2.29 Please describe if you have any thing to share about this study or your experience about off-label prescribing.
Q2.30
Yes No
Do you wish to receive a summary report of this study? 
Display This Question:
If  Do you wish to receive a summary report of this study? Yes  Is Selected
Q2.31 Please provide your e-mail id(s).
 
E-mail id(s)
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Q2.32
Yes No
Researchers at the Department of Pharmacy Administration of the University of Mississippi School of Pharmacy strive to address issues
facing pharmacists, the business and profession of pharmacy, and patient care.  In order to access pharmacists and pharmacy technicians for
future research, the Department intends to develop a research panel.  Such panel will be used for ACADEMIC RESEARCH ONLY.  It is
assured that your email id will be under the safe custody of the Department and managed following professional and ethical norms. 
Do you wish to be considered for inclusion in the research panel being developed by the Department?
If No Is Selected, Then Skip To End of Survey
Display This Question:
If  Researchers at the Department of Pharmacy Administration ... Yes  Is Selected
Q2.33 Please provide e-mail id(s) for participating in the research panel.  In case you wish to be contacted at the address, which you have already
specified, if any, skip this question.
Q2.34  
If   Is Displayed, Then Skip To End of Survey
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APPENDIX C 
Cover Letters 
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Email Cover Letter 1 
Dear Pharmacist, 
 
Subject: Please participate in a Master's thesis project on off-label prescribing 
This is to request your participation in a University of Mississippi-led research project on off-
label prescribing that is largely prevalent in US hospitals. Currently, there is a lack of knowledge 
on pharmacists' beliefs and opinions about off-label prescribing. Such information is believed to 
provide insight on the off-label prescribing practice and may be utilized for the advancement of 
pharmacy practice. 
 
Please complete this short survey (approximately 15 minutes) in a single attempt as partially 
completed responses can NOT be saved for a later attempt and avoid incomplete responses. 
Please be assured that your responses will be kept confidential and anonymous. As an 
appreciation of your time and effort, we offer you a summary report of this study. If you wish to 
participate, please click on the link below. 
 
   http://survey.qualtrics.com/SE?SID=SV_9XLL9OWrNqPKxsE 
 
This study has been approved by the Institutional Review Board (IRB) at the University of 
Mississippi. Should you have any questions or concerns, please contact the University's IRB at 
662-915-7482. Thank you in advance for your time and support. 
 
Sincerely, 
 
Ram Sankar Basak, B.Pharm. 
Graduate Student, University of Mississippi School of Pharmacy 
Faser 211, University, MS 38677 
Phone: 662 801 6484 (M) 
Fax: 662 915 5102 
Email: rsbasak@olemiss.edu  
 
David J. McCaffrey, R.Ph., Ph.D. 
Professor 
University of Mississippi School of Pharmacy 
Faser 217A, University, MS 38677  
Phone: 662 915 5490 (O)  
Email: davidjm@olemiss.edu 
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Email Cover Letter 2 (Reminder) 
Dear Pharmacist, 
Subject: Please participate or complete your participation in an academic off-label prescribing 
study 
This is a friendly reminder about your participation in an off-label prescribing survey. If you 
have already done so, please accept our thanks and disregard this email. 
 
As a pharmacist, your beliefs and opinions about off-label prescribing will provide insight on the 
off-label prescribing practice and may be utilized for the advancement of pharmacy practice. 
 
This survey will take approximately 15 minutes to complete. Please complete it in a single 
attempt because partially completed responses can NOT be retrieved after you close the browser. 
If you have not completed the survey previously, please do now as partly completed responses 
may NOT be analyzable. Please be assured that your responses will be kept confidential and 
anonymous. As an appreciation of your time and effort, we offer you a summary report of this 
study. If you wish to participate, please click on the link below. 
 
   http://survey.qualtrics.com/SE?SID=SV_9XLL9OWrNqPKxsE 
 
This study has been approved by the Institutional Review Board (IRB) at the University of 
Mississippi. Should you have any questions or concerns, please contact the University’s IRB at 
662-915-7482. 
 
Thank you in advance for your time and support. 
 
Sincerely, 
 
Ram Sankar Basak, B.Pharm. 
Graduate student 
University of Mississippi School of Pharmacy 
Faser 211, University, MS 38677 
Fax: 662 915 5102 
Email: rsbasak@olemiss.edu  
 
David J. McCaffrey, R.Ph., Ph.D. 
Professor 
University of Mississippi School of Pharmacy 
Faser 217A, University, MS 38677 
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Phone: 662 915 5490 
Email: davidjm@olemiss.edu 
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Dear Dr White, 
Subject: Request for access to members for an academic research 
Off-label prescribing – especially, for medications prescribed for uses other than their approved 
ones – has garnered the attention of many stakeholders in healthcare, including physicians, 
lawmakers, and payers.  Although off-label prescribing is believed to be driven by unmet 
pharmacotherapeutic needs it, if not practiced judiciously, has the potential of causing 
detrimental effects because of reasons including but not limited to the fact that safety and 
efficacy/effectiveness of such use may not be well assessed.  Unfortunately, pharmacists’ beliefs 
and attitudes toward this behavior as well as their perceptions of their roles and responsibilities 
in the off-label prescribing process remain largely unexplored.  Researchers at the University of 
Mississippi School of Pharmacy believe that a study on the pharmacists’ role in off-label 
prescribing will generate knowledge that has the potential to improve patient care and advance 
pharmacy practice. 
Because of budgetary constraints and the demands of the research design employed, we have 
determined that an Internet-based survey would be the most appropriate method of data 
collection.  However, we do not have e-mail access to pharmacists who are practicing in 
community hospitals.  As a responsible and caring organization of health-system pharmacists, 
your support of this study will be greatly appreciated.  In other words, we would appreciate your 
organization’s support for this research by sharing our offer to participate with your members.  
We do not require that you send your membership list to us.  However, we require only that you 
forward our request to your pharmacist colleagues. 
Please note that this study will not be fielded until it has met all of the human subject protections 
required by our Institutional Review Board (IRB) and federal law.  We assure you that we will 
maintain professional norms and we will protect the confidentiality and anonymity of your 
members who choose to participate in the study.  As an appreciation of your participation and 
support, we will submit a summary report of the findings of the study to your organization. 
We believe that the results from this Master’s thesis project will have implications for 
pharmacists and facilitate pharmacists' professional advancement.  We will gladly provide 
further information, if needed.  Please let us know at your earliest convenience if you agree to 
participate. 
Thank you in anticipation of your support. 
Sincerely, 
Ram Sankar Basak, B.Pharm. 
Graduate student 
The University of Mississippi School of Pharmacy 
662 801 6484 (M) 
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Email: rsbasak@olemiss.edu 
 
David J. McCaffrey III, Ph.D. 
Thesis Advisor 
Associate Professor 
The University of Mississippi School of Pharmacy 
662 915 5490 (O), 662 915 5102 (F) 
Email: davidjm@olemiss.edu 
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VITA 
Ram Sankar Basak was born in 1973 in India.  Ram is the son of Dhirendra Nath Basak 
and Kalpana Basak.  Ram completed his Bachelor’s of Pharmacy from Jadavpur University in 
Calcutta, India.  After his graduation, Ram worked for a couple of years as a marketing 
professional for an Indian pharmaceutical company.  Due to his passion for learning, Ram joined 
the Department of Pharmacy Administration of the University of Mississippi in 2005 in order to 
pursue his Master’s degree with emphasis in pharmaceutical marketing.  Ram completed his MS 
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